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ABSTRACT
The focus of this work is structural and functional studies of wild-type and 
active-site mutants of human adenosine deaminase. Two active-site amino acids, 
Glu217 and His238, were previously substituted with alanine by site-directed 
mutagenesis. The Glu217Ala and His238Ala mutants showed little or no changes in 
Zn content and Km value, yet dramatic loss of enzyme activity. Circular dichroism 
studies of the solution conformation of wild-type and mutant human adenosine 
deaminases indicate that 30 to 50% of a-helical structure is lost in Glu217Ala and 
His238Ala, respectively, whereas (3-sheet structure is fully retained. Inhibitor 
binding is measured by a fluorescent assay. Dissociation constants for transition- 
state analog inhibitors are similar for wild-type and mutant enzymes, suggesting that 
inhibitor and substrate binding determinants are preserved in the mutants. Protein 
stability studies show that Glu217Ala and His238Ala are less stable to thermal, urea, 
and guanidinium chloride denaturation than wild-type. Because the enzyme 
conformational changes caused by substitution o f Glu217 and His238 mainly 
destabilizes the protein with only minor effects on substrate and inhibitor binding, 
the loss of enzyme activity is probably due to the modification of functional groups 
that are critical for catalysis. The active-site Zn environment o f wild-type, 
Glu217Ala, and His238Ala mutant adenosine deaminases is probed by EXAFS. 
There are five ligands coordinated to Zn in the free enzyme and ground- and 
transition-state analog inhibitor complexes of these three adenosine deaminases, 
suggesting the presence o f a water/hydroxide or a hydroxyl group. Zn-ligand 
distances of the mutants are similar to those o f the wild-type, indicating that the 
active-site of mutants are intact upon substitution. Wild-type and His238Ala form a 
transition state with the transition-state analog inhibitor purine riboside whereas with
ix
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Glu217Ala a ground state is formed. The findings are consistent with the proposed 
catalytic mechanism based on the X-ray crystal structure o f mouse adenosine 
deaminase, and provide further insight into the effects of these active site residues on 
the structure, stability and function o f human adenosine deaminase.
x
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CHAPTER 1: INTRODUCTION
Adenosine Deaminase Background
Adenosine deaminase (ADA, adenosine aminohydrolase, EC 3.5.4.4) is a 
purine salvage pathway enzyme that catalyzes the irreversible deamination of 
adenosine and deoxyadenosine to inosine and deoxyinosine, respectively. The 
enzyme has been isolated as a soluble single polypeptide from erythrocytes 
(M.W.=36,000) (Van der Weyden & Kelly, 1976), and from leukemic cells and 
thymus (M.W.=41,000) (Wiginton et al., 1981). Adenosine deaminase is present on 
the cell surface, as well as in the cytoplasm of all cells, such as human fibroblasts, 
rabbit renal tubular cells, and human mononuclear blood cells (Van der Weyden & 
Kelly, 1976; Andy & Komfeld, 1982; Schrader et al., 1988; Aran et al., 1991), with 
high enzyme activity present in lymphoid tissue (Carson et al., 1977) and highest 
activity present in the gastrointestinal tract (Witte et al., 1991). The human 
adenosine deaminase protein is encoded by a single gene on the long arm of 
chromosome 20 (Tischfield et al., 1974) that has 12 exons separated by 11 introns 
and spans about 32,000 base pairs (bp) o f DNA (Wiginton et al., 1986). In lung and 
kidney, adenosine deaminase has also been associated with a ADA binding protein 
and appeared as a dimeric membrane-bound "complexing protein" (M.W.=298,000) 
(Schrader & Stacy, 1969; Daddona & Kelley, 1970; Daddona & Kelly, 1979) . At 
first the function of the association was not ascertained (Schrader et al., 1990). More 
recent studies are focused on two sets o f proteins: CD26, a 110-kD glycoprotein 
playing an integral role in T cell activation; and p43, a 43 kD protein which can be 
recognized by antibody to CD26. The results suggest that two peptides derived from 
p43 are completely identical to those o f residues 35-64 and 172-206 of the human
1
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adenosine deaminase, and CD26 is identical to adenosine deaminase binding protein of 
the dimeric "complexing protein" (Kameokaet al., 1993).
Adenosine deaminase has a central role in the maintenance of immune function 
and competency. In humans, an absence or deficiency o f functional adenosine 
deaminase catalytic activity is associated with severe immunodeficiency and 
lymphopenia in both T- and B-cell lineages (Giblett et al., 1972; Coleman et al., 
1978). An inherited deficiency of adenosine deaminase activity accounts for 
one-fourth of all severe combined immunodeficiency disease (SCID), which is a rare 
human hereditary disorder characterized by the absence of mature T and B 
lymphocytes, in children (Dissing & Knudsen, 1972; Parkman et al., 1975; Martin & 
Gelfand, 1981). These effects are believed to be mediated by the build-up of 
deoxyadenosine in mostly lymphoid cells as well as urine, plasma, bone marrow cells, 
and erythrocytes (Mills et al., 1976) which is converted to the ultimate toxic metabolite 
deoxyadenosine triphosphate (dATP) (Dissing & Knudsen, 1972; Parkman et al., 
1975; Chen et al., 1978; Cohen et al., 1978a; Cohen et al., 1978b; Coleman et al., 
1978; Donofrio et al., 1978; Fox & Kelley, 1978; Martin & Gelfand, 1981). Deoxy- 
ATP formation is increased in incubated erythrocytes (Agarwal et al., 1976) and 
lymphocytes (Raivio et al., 1977), and dATP concentration in lymphocytes is ten 
times greater than the normal value (Polmar et al., 1976). It is unclear why lymphoid 
tissue (specifically immature T-cells) has a higher associated enzyme activity of 
deoxyadenosine phosphorylating enzymes (Carson et al., 1977) generating higher 
levels of the toxic dATP metabolite (Donofrio et al., 1978) than other tissues. It is 
also unclear why lymphoid cells are especially sensitive to high levels o f this dATP 
metabolite (Coleman et al., 1985), although the potent inhibition of dATP to the 
enzyme ribonucleotide dephosphate reductase (Thelander & Reichard, 1979) and the 
rate limiting step in DNA synthesis would likely affect the extensive cell turnover seen
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3in this lineage (Carson et al., 1977). Other lineages turn over rapidly also, and it may 
be then that the expression of terminal transferase in lymphoid cells in combination 
with increased ATP levels is actually generating the lethal effect.
In principle, the adenosine deaminase deficiency disease could be treated by 
supplying a source of active adenosine deaminase, which will bring down the levels of 
toxic metabolites allowing lymphocyte differentiation to proceed (Vega, 1992). 
Various therapeutic strategies have been utilized to solve the fatal (by 1-2 years of age) 
[Pollara, 1979 #18] deficiency o f adenosine deaminase enzyme activity. Bone marrow 
transplantation from allogeneic donors results in the repopulation of the blood cells of 
the ADA' infants and the correction of the deficiency, however, only one-third of all 
patients have a matched donor (Parkman et al., 1975; Kantoff et al., 1988). Treatment 
has also been effective by normal red-cell transfusions of ADA+ erythrocytes (Polmar 
et al., 1976) although the promising outcome of overcoming the deficiency has been 
short-lived in many infants. Injection of polyethylene glycol-modified bovine 
adenosine deaminase (PEG-ADA) has also been administered (Hershfield et al., 1987) 
and promising results have been obtained since much more PEG-ADA can be given 
than in red-cell transfusions. Therefore, the blood activity levels are increased and 
potent transfusion side effects including iron build-up and risks of viral infection are 
reduced in PEG-ADA treatment. In the late eighties, adenosine deaminase deficiency 
SCID was also selected as the first target for human gene therapy replacement 
protocols using modified retroviral vectors containing the ADA-cDNA (Kantoff et al., 
1986; Anderson, 1990; Culver et al., 1991). In this approach, the ADA' SCID patient 
is reimplanted with autologous T  lymphocytes which have received an active copy of 
the ADA-gene by retroviral vector-mediated gene transfer and have thereby been 
converted into ADA+ cells. The activity of the retrotransfected ADA' gene product is 
expected to restore the immuno-competence of the recipient (Ferrari et al., 1991). The
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
experiment constitutes the first gene therapy trial on humans (Culliton, 1990). Clinical 
trials of augmentation therapy using this technique are underway. The most recent 
approach is a gene correction therapy (Vega, 1992). Among other desirable common 
properties for gene therapy, gene correction principally keeps the original expression 
properties of the corrected gene and avoids the introduction o f foreign (retroviral or 
others) sequences into the genome of human being(Vega, 1991).
The overproduction o f adenosine deaminase, which causes a 45-70 fold 
increase of erythrocyte adenosine deaminase activity in humans, has been observed in 
kindred with severe hereditary hemolytic anemia's (Valentine et al., 1977). Patients 
with this dominantly inherited entity have a mild anemia and decrease of erythrocyte 
adenosine nucleotides to less than 50% of that of comparable reticulocyte-rich blood. 
The increased adenosine deaminase activity is also associated with some leukemias 
(Coleman & Hutton, 1975). Potent inhibitors of adenosine deaminase have been used 
alone or in combination with other drugs as antimetabolic, antineoplastic, and 
antibiotic agents to treat certain leukemias in humans (Fox & Kelley, 1978; Coleman, 
1983). The underlying mechanism for overexpression o f the gene and its 
consequences are unknown.
Furthermore, since adenosine deaminase is a key enzyme in adenosine 
metabolism, it also affects cellular levels of adenosine. Many biological properties of 
adenosine are identified: (1) It is toxic to mammalian and bacterial cells; (2) Its 
presence is associated with inhibition of the immune response, coronary vasodilation, 
delayed neurotransmission, inhibition or stimulation of hormone secretion, and 
changes in the m etabolism  of a number o f tissues such as lipolysis, and 
glycogenolysis. Adenosine also has many biochemical effects including: direct 
activation of adenylate cyclase, inhibition o f pyrimidine biosynthesis, and diminution 
of phosphoribosyl-pyrophosphate (PP-ribose-P) synthesis (Robio et al., 1969;
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5Bumstock, 1972; Chagoya de Sanchez et al., 1974; Fain & Wieser, 1975; Fox & 
Kelley, 1978).
In addition to its deaminating activity, adenosine deaminase also catalyzes the 
hydrolysis of several 6-substituted purine derivatives including a number of clinically 
important antimetabolites (Zielke & Suelter, 1971). At least 80 compounds are known 
to bind to adenosine deaminase, some as substrates but most as inhibitors that show 
different types o f inhibition (Wilson & Quiocho, 1993). Some of these inhibitor 
compounds have been instrumental in postulating a reaction mechanism for adenosine 
deaminase. Phosphorylated nucleosides are not substrates or inhibitors for adenosine 
deaminase (Zielke & Suelter, 1971). Understanding the catalytic mechanism of 
adenosine deaminase is of special interest because analog inhibitors of adenosine with 
chemotherapeutic potential (Agarwal, 1982) as well as drugs directed against other 
enzymes are degraded by adenosine deaminase. These drugs could be modified to 
have a longer pharmacological half-time if it were understood how adenosine 
deaminase interacts with these compounds.
The actual catalytic mechanism employed by adenosine deaminase in the 
deamination reaction of adenosine and deoxyadenosine has been the subject of much 
speculation for more than two decades. Studies using competitive inhibitors, usually 
transition and ground-state analogs (Kati & Wolfenden, 1989b), have implicated a 
histidine residue of the protein as hydrogen bonding to the sixth position -OH group of 
the hydrated purine intermediate. It is proposed that the deamination reaction actually 
proceeds by direct water attack (addition-elimination mechanism) (Kurz & Frieden, 
1987) rather than by a double-displacement mechanism (Jones et al., 1989). Indeed, 
the importance o f hydrogen bonding to site 6 o f the purine in stabilizing the 
rate-determining tetrahedral intermediate (Kurz & Frieden, 1987) is seen in the 
observation that K( for the competitive inhibitor of adenosine deaminase containing an
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
6-OH group at site 6 is lO^-fold lower than that observed for the hydrogen substituted 
moiety (Kati & Wolfenden, 1989a) Other potential groups implicated in the reaction 
mechanism are carboxyl (Kati & Wolfenden, 1989a) and imidazole moieties (Kurz & 
Frieden, 1983).
Time-resolved fluorescence spectroscopy has also been used (Philips et al., 
1987; Philips et al., 1989) to demonstrate that adenosine deaminase undergoes 
conformational changes upon binding inhibitors. This also may serve to stabilize the 
proposed tetrahedral intermediate and thus increase the catalytic efficiency of 
the enzyme.
The adenosine deaminase catalyzed deamination appears to be encounter 
limited (Kurz et al., 1992) with a kcat o f 375 s*1 and a fccat/K m of 1.4 x 107 M_1 s_I. 
The rate enhancement of approximately 2 x 1012 (Frick et al., 1987) shows this 
enzyme to be more efficient than has been described previously (Wolfenden & Kirsch, 
1968). Support for the enzyme mechanism proceeding via formation of a tetrahedral 
intermediate has come from several studies (Wolfenden et al., 1969; Evans & 
Wolfenden, 1973; Kurz & Frieden, 1983). l3C NMR studies with purine riboside 
showed that hybridization of C-6 changes from sp2 to sp3 in the binary complex (Kurz 
& Frieden, 1987) with the nucleophile at C-6 being either a water molecule or a thiol at 
the active site of the enzyme. Subsequent NMR and UV absorption studies (Jones et 
al., 1989) gave evidence that the substrate was bound as a 1,6 covalent hydrate.
Further suggestions on residues involved in mechanisms o f adenosine 
deaminase catalytic activity have been provided by a comparison of the amino acid 
sequences of the & coli. mouse and human forms of adenosine deaminase (Chang et 
al., 1991). In this study, a comparison was also made with eukaryotic AMP 
deaminases, which have an analogous function, in order to identify potential catalytic 
residues solely on the basis of functional conservation. Four residues (His214,
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
7Cys262, Asp295 and Asp296) were assigned putative catalytic roles. These residues 
are compatible with those suggested from the ground-state and transition-state analog 
studies outlined above.
The key to the understanding o f the catalytic mechanism of adenosine 
deaminase came with the publication in 1991 of the crystal structure (2.4 A resolution) 
o f mouse adenosine deaminase complexed to a nearly ideal transition-state analog 
inhibitor 6(R)-hydroxyl-l,6-dihydropurine riboside (Wilson et al., 1991). The 
adenosine deaminase protein was purified from an overexpressing E\ coli strain 
containing a plasmid with the mouse adenosine deaminase sequence and complexed to 
purine riboside, the transition state analog inhibitor. Adenosine deaminase was found 
to contain 8 central (3 strands and 8 peripheral a-helices in a barrel format. Mouse 
adenosine deaminase was also found to complex a previously undetected Zn moiety in 
the active site with 4 amino acid residues involved in lending the Zn coordination. 
His214 and Asp295 (as identified by (Chang et al., 1991) both appear to be involved 
in coordinating the Zn molecule. In fact, Asp295 seems to have a dual role in that it 
also acts as a general base in the proposed addition-elimination (with tetrahedral 
intermediate) catalytic mechanism (Wilson et al., 1991). Residues at sites Glu217, 
glyl84, Asp296 (as identified by Chang et al., 1991) and His238 are proposed to be 
directly involved in the catalytic mechanism. This agrees well with the identification of 
conserved residues between functionally similar proteins (Chang et al., 1991; Wilson 
et al., 1991). The Cys residue at site 262 (as identified by Chang et al., 1991), 
however, is believed not to have any functional role in the catalytic mechanism. In 
fact, none of the 5 Cys residues in the polypeptide chain are implicated.
The most recent enzyme catalytic mechanism (Figure 1.1) was proposed based 
on the X-ray crystal structures o f mouse adenosine deaminase complexed with a 
transition-state analog inhibitor 6(R)-hydroxyl-1,6-dihydropurine riboside and a
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ground-sate analog inhibitor 1-deazaadenosine, in which Zn plays a crucial role by 
facilitating formation of a pre-transition state with a bound activated water molecule or 
a hydroxide (Wilson & Quiocho, 1993). In this mechanism, Glu217, which is ideally 
located coplanar with the purine ring, donates a proton to N 1 o f substrate adenosine, 
thereby reducing the N1-C6 double bond character and rendering C6 susceptible to 
nucleophilic attack and transformation from sp2 to sp3 in the tetrahedral adduct. 
His238 acts as a general base/acid and plays an important role in enzyme catalysis. 
Asp295 remains coordinated to the Zn and is considered to hydrogen bond to the 
activated water or hydroxide and optimize the geometry for the hydroxide addition to 
the C-6 of adenosine. Thus, the tetrahedral intermediate is formed. Formation rather 
than decay of the tetrahedral intermediate is believed to be the most difficult (possibly 
rate-limiting) step (Kurz & Frieden, 1987). A Zn-activated water or a hydroxide is 
proposed to be the attacking nucleophile according to the mouse ADA/HDPR and 
ADA/DAA X-ray crystal structures and the abstracted proton on Ne2 of His238 attacks 
the N6 amino leaving group. However, the proton source for the leaving -NH2 group 
is far from certain since this leaving group would be pushed into an essentially 
hydrophobic environment; the proton may come from the incipient hydroxyl group, 
shuttled by the Asp295 (Wilson & Quiocho, 1994). The precise chirality of the 
chemical reaction is dedicated by the favorable geometry together with the location of 
the Zn and Asp295 in the B-face side of the purine as hydroxide attack occurs on this 
side only. The key point of the proposed mechanism is the activation of the water, 
which is believed to involve coordination of the oxygen to the powerful Zn 
electrophile, donation of one hydrogen to a hydrogen bond with 051 of Asp295, and 
donation of the other hydrogen to a hydrogen bond Ne2 o f His238.
Adenosine deaminase was recently reported to bind the reaction product 
inosine as its 1,6-hydrate, a gem-diol that appears to be even more closely analogous
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Figure 1.1. Catalytic mechanism of adenosine deaminase based on X-ray Crystal structure results of mouse enzyme (Wilson & 
Qiuocho, 1993).
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than purine riboside, to highly activated intermediates in substrate deamination (Wilson 
& Quiocho, 1994). Indeed, the structure of the proposed gem -diol would bear an 
even closer resemblance to a tetrahedral intermediate in oxygen exchange from water 
into inosine, a reaction earlier found to be catalyzed by adenosine deaminase 
(Wolfenden & Kirsch, 1968). It was also suggested most recently that although 
covalent hydrates are formed as high-energy intermediates during catalysis by 
adenosine deaminase, it is unlikely to accumulate at the active site. In contrast with 
this actual reaction intermediate, the hydrated form of purine riboside, in which 
hydrogen replaces the leaving group -NH2 , is able to accumulate at the active site 
because its equilibrium of hydration is much less favorable (about 10-7 M) and can be 
overcome by forces o f attraction at the active site (Shih & Wolfenden, 1996).
While much is now known about the enzymatic activity of human ADA, 
including its interactions with various substrates (Wiginton et al., 1981) and inhibitors 
(Kurz & Frieden, 1987; Philips et al., 1987; Philips et al., 1989), no direct 
information is available concerning the enzyme active site.
Various natural point mutations of the amino acid sequence of human 
adenosine deaminase have been described (Akeson et al., 1989; Medin et al., 1990), 
and some functional implications examined (Wilson et al., 1991). The locations of 8 
point mutations derived from sequencing complementary DNAs from cell lines derived 
from SCID patients are outlined in relation to the structural changes made (Akeson et 
al., 1989). All o f these site-specific mutations are in regions of the protein that will 
likely disrupt the folded structure of the enzyme but will not directly affect the catalytic 
mechanism. It is expected that active-site mutations, lacking any functional activity, 
would be lethal and selected against. Therefore little information can be gained from 
the analyses of these existing mutations.
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The demonstration that human recombinant adenosine deaminase can be 
overexpressed in and purified from insect larvae (Medin et al., 1990) combined with 
techniques for readily introducing site-specific mutations in cDNA has led to an 
increased interest in examining the proposed catalytic mechanism of human adenosine 
deaminase. It is now possible to introduce site-specific changes that directly affect 
catalysis while the disruption o f the folding of the enzyme is minimized since the 
three-dimensional structure is known. It is also now possible to overproduce these 
altered proteins in a system amenable to the production and purification o f variant 
enzyme forms for detailed enzyme analyses.
The functional role of amino acid residues in or close to the active site of 
adenosine deaminase has been probed by site-directed mutagenesis of the human 
enzyme based on the X-ray crystal structure of mouse enzyme (Bhaumik et al., 1993). 
The human enzyme has 11 additional amino acids at the C-terminus and over 80% 
homology with the murine enzyme in the rest o f the sequence. The active site residues 
are completely conserved. Replacement o f four amino acid residues in the active site 
with alanine: H isl7, His214, Glu217, and His238, caused dramatic loss of enzyme 
activity though the enzyme still had a bound Zn. The His 17Ala and His214Ala 
mutants gave low protein yields during purification. However, the Glu217Ala and 
His238Ala mutants could be isolated in excellent yield and purity.
Extended X-Ray Absorption Fine structure
Since X-rays have wavelengths on the order o f atomic dimensions, these 
highly energetic photons can be used to elucidate the molecular structure of materials. 
One example is X-ray absorption spectroscopy (XAS). A typical X-ray absorption 
spectrum is shown in Figure 1.2. At a well-defined X-ray photon energy, a sharp rise 
in absorption coefficient is observed. This is called an X-ray absorption edge and is 
due to electron dissociation from a core level of one type of atom (the absorbing atom).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Figure 1.2. An X-ray absorption spectrum plotted as absorption coefficient versus 
photon energy. Bottom, full spectrum showing the pre-edge and EXAFS regions. 
Top, expanded view of the edge region (Scott, 1985).
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Above the edge, the quasi-periodic modulations in the X-ray absorption coefficient are 
referred to as extended X-ray absorption fine structure (EXAFS). EXAFS refers to 
both the quasi-period modulations in the x-ray absorption coefficient above the x-ray 
absorption edge and also to the techniques used to analyze them in terms of molecular 
structure. The analysis of EXAFS may lead to direct information about the local 
environment around the absorbing atom. The EXAFS technique yields radial 
structural information within a 4-5 A radius around the absorbing atom. Specifically, 
the question to be answered by EXAFS is: "How many o f what type of atom are at 
what distance from the absorbing atom?" Since EXAFS only gives radial distance 
information, orientation of the absorbing atom sites within a sample is not important. 
Amorphous samples (e.g., powders, solutions, frozen solutions, gases) are amenable 
to study by this technique.
The X-ray absorption spectrum of a given sample will exhibit an edge at a 
photon energy equal to the ionization potential of a bound electron in the constituent 
atoms of the sample. Scanning the photon energy causes every atom in the sample to 
give rise to several absorption edges, which are named for the shells of the Bohr atom 
(K, L, M, etc.) as the photon energy matches the ionization potential of each bound 
electron as illustrated in Figure 1.3.
In the quasi-periodic modulations in the EXAFS region, the X-ray photons 
absorbed have a higher energy than that necessary to ionize the absorbing atom. 
Defining the X-ray absorption edge energy as Eo (the threshold energy) and assuming 
a photon energy of E (E>Eo), the extra energy E-Eo is transferred into kinetic energy 
of the photoelectron, which is also a photoelectron wave. The kinetic energy of the 
photoelectron changes throughout the EXAFS region by energy scanning of the 
incident X-ray radiation. In a condensed media, such as liquids or solids, an 
absorbing atom is surrounded by neighboring atoms called scattering atoms.
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Figure 1.3. Schematic diagram relating the X-ray absorption spectrum to the atomic 
energy level diagram. X-ray photon absorption is indicated by the arrows in the 
energy level diagram, each giving rise to an absorption edge in the top spectrum. 
Some Lin and K X-ray absorption edge energies are tabulated below the diagram 
(Scott, 1985).
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Considering the simplest possible arrangement of atoms, a diatomic molecule with an 
absorbing atom a and a scattering atom s is shown in figure 1.4. The photoelectron 
wave propagating from a and scattering from s are shown in solid and dashed arcs, 
respectively. Figure 1.4a shows that, for energy E j, the amplitude o f the 
backscattered photoelectron wave at the absorbing atom a  is a maximum with the 
dashed arc through a, thus giving rise to a maximum in the modulation o f XAS as 
shown in Figure 1.4c. Increasing the photon energy to E2  generates a photoelectron 
with a shorter wavelength (larger energy), the scattering of which is illustrated in 
Figure 1.4b. At E2 , the backscattered photoelectron has a minimum amplitude at atom 
a, generating a minimum in XAS as shown in Figure 1.4c. It is demonstrated that the 
EXAFS region is a periodic modulation of X-ray absorption as the photoelectron 
wavelength is scanned and the backscattered photoelectron wave periodically goes in 
and out of phase with the outgoing photoelectron wave (an interference effect). Since 
EXAFS modulation depends on the nature and location of the scattering atom s , proper 
analysis of EXAFS can elucidate the local structure around the absorbing atom a as 
following: The neighboring atoms of absorbing atom a contribute a series of damped 
sine waves to the overall EXAFS spectrum of a , which can be described by three 
measurable quantities - frequency, amplitude, and phase. The frequency of the sine 
wave is a measure of the distance between a and scattering atoms, the amplitude of the 
sine wave is a measure of the number of a certain type o f scattering atoms at that 
distance, and both the amplitude and the phase of the sine wave help define the identity 
of scattering atoms around the absorbing atom a. In a word, as mentioned before, 
EXAFS can determine how many of what type o f atoms at what distance from the 
absorbing atom a.
Besides the single-scattering theory of EXAFS discussed above, there is also 
the multiple-scattering phenomenon for EXAFS that the photoelectron encounter two
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Figure 1.4. Diagram of photoelectron waves generated by X-ray absorption at two 
different energies, (a) and (b) indicate the photoelectron scattering for energies E[ and 
E2 , respectively, as indicated in the spectrum in (c). In (a), the scattered photoelectron 
has a maximum amplitude at the absorbing atom a and in (b), the scattered 
photoelectron has a minimum amplitude at atom a. This leads to a maximum and 
minimum, respectively, in the EXAFS shown in (c) (Scott, 1985).
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Figure 1.5. One possible multiple-scattering pathway for a photoelectron generated by 
X-ray absorption by atom a in the presence of two scattering atoms S[ and S2- The 
scattering pathway indicated is a The multiple-scattering contribution to the
EXAFS depends on the distances involved and on the angles 0i and 02 (Scott, 1985).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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or more scattering atoms in its "round trip" back to the absorbing atom a (Figure 1.5). 
When atoms (including the X-ray absorbing atom a and its neighbor) are arranged in a 
linear or near collinear fashion, such as CN- or CO- in imidazole or carboxyl, the 
forward scattering will be strongly enhanced and EXAFS contributions from 
neighboring atoms as far as 8 A can be observed (Teo, 1981). The single-scattering 
theory of EXAFS is not applicable in these situations and multiple-scattering processes 
involving the intervening atoms should be taken into account in order to provide 
accurate structural characterization of the scattering atoms around the absorbing metal 
atom a.
Zn plays a crucial role in the proposed catalytic mechanism of adenosine 
deaminase. However, information concerning Zn environment has been rather limited 
so far. Because of its filled 3d-shell, Zn molecule is not accessible by spectroscopic 
techniques such as optical absorption, NMR, and EPR. Although Zn sites in proteins 
may be studies indirectly by spectroscopy, such as Cd substitution and monitoring by 
113Cd NMR spectroscopy or Co substitution and monitoring by UV-visible or CD, 
these surrogates may not be faithful reporters of Zn sites. XAS in general, and 
EXAFS in particular, offer a unique and direct probe o f Zn centers in proteins. In the 
work of this dissertation, EXAFS is successfully used to monitor the structural 
changes of ligands coordinated to the active-site Zn in free wild-type, Glu217Ala and 
His238Ala mutant human adenosine deaminases and their ground- and transition-state 
analog inhibitor complexes.
This dissertation is based on two manuscripts individually submitted to 
Biochemistry.
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CHAPTER 2: SPECTROSCOPIC STUDIES OF ACTIVE SITE MUTANTS 
OF HUMAN ADENOSINE DEAMINASE
Introduction
Adenosine deaminase (EC 3.5.4.4) is an important enzyme in the purine 
salvage pathway which catalyzes the irreversible hydrolytic deamination of 
adenosine or deoxyadenosine to their respective inosine product and ammonia. 
Adenosine deaminase is present at varying levels in the cytoplasm of virtually all 
animal tissues and microorganisms. Because it plays a central role in maintaining 
immune competence and function, adenosine deaminase has become a focus of 
interest for structure-function studies o f the molecular basis of genetic disease.
Adenosine deaminase has been isolated as a soluble single polypeptide of 
different electrophoretic mobilities and molecular weights from erythrocytes, 
leukemic cells, and thymus (Van der Weyden & Kelly, 1976; Carson et al., 1977; 
Wiginton et al., 1981). In humans, adenosine deaminase exists as either a small 
catalytically active protein or complexed to the ADA binding protein, recently 
suggested to be the T cell activation antigen, CD26 (Van der Weyden & Kelly, 1976; 
Daddona & Kelly, 1979; Daddona et al., 1984; Kameoka et al., 1993; Morrison et al., 
1993). It is present with high enzyme activity in lymphoid tissue and the 
gastrointestinal tract. An absence or deficiency of functional adenosine deaminase is 
associated with severe immunodeficiency and lymphopenia in both T- and B-cell 
lineages. Inherited deficiency of the enzyme accounts for one fourth of all severe 
combined immunodeficiency disease in children (Giblett et al., 1972; Hirschhom et 
al., 1979; Hirschhom et al., 1983). The deleterious effects are believed to be 
mediated by the build-up of adenosine and deoxyadenosine in lymphoid cells, which 
are converted to the ultimate toxic metabolite deoxyadenosine triphosphate (Carson
23
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
24
et al., 1977; Coleman et al., 1978; Fox & Kelley, 1978; Martin & Gelfand, 1981). 
The overproduction of adenosine deaminase in humans has been linked with severe 
hemolytic anemia and some leukemias (Van der Weyden & Kelly, 1976; Valentine 
et al., 1977; Fox & Kelley, 1978; Smyth et al., 1978). Potent inhibitors of adenosine 
deaminase have been used alone or in combination with other drugs as antimetabolic, 
antineoplastic, and antibiotic agents to treat certain leukemias in humans (Fox & 
Kelley, 1978; Coleman, 1983). Furthermore, since adenosine deaminase is a key 
enzyme in adenosine metabolism, it also affects cellular levels o f adenosine, which is 
an endogenous anticonvulsant and antihypoxic as well as a m odulator of 
neurotransmission, coronary blood flow, lipolysis, and glycogenolysis (Robio et al., 
1969; Bumstock, 1972; Chagoya de Sanchez et al., 1974; Fain & Wieser, 1975; Fox 
& Kelley, 1978).
The catalytic mechanism of the deamination reaction o f adenosine and 
deoxyadenosine has been the subject of much speculation for over 20 years. A 
number of mechanisms have been proposed by different groups using ground- and 
transition-state analog inhibitors (Wolfenden et al., 1967; Wolfenden et al., 1977; 
Kurz & Frieden, 1983; Kurz et al., 1985; Frick & Wolfenden, 1986; Frick et al., 
1987; Weiss et al., 1987; Jones et al., 1989; Kati & Wolfenden, 1989; Kati et al., 
1992; Grosshans & Wolfenden, 1993; Adler & Wolfenden, 1994). A hydrate 
tetrahedral intermediate of purine riboside was first observed in I3C NMR studies of 
calf intestine adenosine deaminase (Kurz & Frieden, 1987) and subsequently in the 
X-ray crystal structure o f mouse adenosine deam inase com plexed to 
1,6-dihydropurine riboside (Wilson et al., 1991; Sharff et al., 1992). Time-resolved 
fluorescence spectroscopy has also been used to demonstrate conformational changes 
in adenosine deaminase upon inhibitor binding which may serve to stabilize the 
tetrahedral intermediate (Philips et al., 1987; Philips et al., 1989). The X-ray crystal
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
structure also revealed adenosine deaminase to be a metalloenzyme containing one 
mole of Zn per mole of protein. The enzyme has an oc/p barrel structure consisting 
of eight p strands connected by eight a  helices. The active site is well-buried in the 
C-terminal end o f the barrel with the Zn lying in the deepest part o f the active site 
pocket. The Zn is coordinated by five atoms from H isl5, H isl7, His214, Asp295, 
and 1,6-dihydropurine riboside. A catalytic mechanism was recently proposed based 
on the crystal structure o f mouse adenosine deaminase bound to a ground state 
analog 1-deazaadenosine (Wilson & Quiocho, 1993). An activated water molecule 
attacks the substrate at the 6-position of the purine ring to form the tetrahedral 
intermediate. The Zn plays a central role in this mechanism.
The functional role o f amino acid residues in or close to the active site of 
adenosine deaminase has been probed by site-directed mutagenesis o f the human 
enzyme based on the X-ray crystal structure o f the mouse enzyme (Wilson et al., 
1991; Bhaumik et al., 1993). The human enzyme has 11 additional amino acids at 
the C-terminus and over 80% homology with the mouse enzyme in the rest o f the 
sequence. The active site residues are completely conserved. Replacement o f four 
amino acid residues in the active site with alanine: His 17, His214, Glu217, and 
His238, caused dramatic loss of enzyme activity though the enzyme still had a bound 
Zn. The X-ray structure shows that His 17 and His214 coordinate the active-site Zn, 
while Glu217 and His238 bind the ligand in the transition state. The H isl7A la and 
His214Ala mutants gave very low protein yields during purification. However, the 
Glu217Ala and His238Ala mutants could be isolated in excellent yield and purity. 
In the recent proposed catalytic mechanism of adenosine deaminase, Glu217 donates 
a proton to N1 o f substrate adenosine. This reduces the N1— C6 double bond 
character, making C6 susceptible to nucleophilic attack and transformation from sp2 
to sp3 in the tetrahedral adduct. His238 acts as a general base and attracts a proton
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from a Zn-activated water to create a pre-transition state. The abstracted proton on 
Ne2 of His238 then serves as a proton donor to the N6 amino leaving group of 
adenosine (Wilson & Quiocho, 1993). In order to confirm  the pivotal roles of 
Glu217 and His238 in catalysis, it is important to establish that the loss o f enzyme 
activity is not due to protein conformation changes. In this paper, protein secondary 
structure changes are determined by CD spectral analysis using the convex constraint 
algorithm (Perczel et al., 1992a). The binding of transition-state analog inhibitors to 
wild-type and mutant human adenosine deaminases is measured in a fluorescent 
assay. The stability o f the wild-type and mutant proteins to temperature and 
denaturants is monitored by CD spectroscopy. The results provide further insight 
into the relationship between protein conformation and enzyme activity in adenosine 
deaminase.
M aterials and M ethods
Materials. Adenosine and inosine are purchased from Sigma Chemical Co. 
(St Louis, MO). Urea is ultra pure, enzyme grade from Life Technologies, Inc. 
(Gaithersburg, MD). Guanidinium chloride is ultra pure grade from Amresco 
(Solon, OH). 2-aminopurine riboside is synthesized by the method of Fox et al. 
(1958). All other reagents are of the highest commercial grade. Recombinant 
wild-type human adenosine deaminase is purified by adenosine affinity 
chromatography (Medin et al., 1990; Bhaumik et al., 1993). Mutant enzymes 
His238Ala and Glu217Ala are purified by using a monoclonal antibody column 
(Bhaumik et al., 1993) or a purine riboside affinity column (Santoro & Bolen, 1988). 
Enzyme stock solutions are stored in 10 mM sodium phosphate buffer, pH 7.4, 140 
mM NaCl. Concentration ranges and specific activities for wild-type, Glu217Ala, 
and His238Ala are 8.4 - 24, 2.3 - 8.1, and 2.0 - 3.3 x 10*5 M; and 450, 0.04, and 0.12
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units/mg, respectively. Protein concentration is determined by the Bradford method 
and molarity is calculated using a molecular weight of 41,000.
Circular Dichroism. Circular dichroism measurements are made on an AVTV 
model 62DS spectropolarimeter equipped with a model W5TZ-105 thermoelectric 
temperature controller. Data for the respective blank solution are recorded and 
subtracted from the adenosine deaminase data. The molar ellipticity [0] in deg cm2 
dmol*1 is calculated from
[0] = eobsMWR/lOcl (1)
where 0obs is the measured ellipticity in millidegree, MWr is the mean residue 
molecular weight o f the protein (41,000 molecular weight divided by 363 amino 
acids), c is protein concentration in mg/mL, and I is the optical pathlength o f the cell 
in cm.
Secondary structure of wild type and mutant adenosine deaminases is 
determined from their CD spectra between 178 nm and 240 nm recorded using a 5 s 
time constant, 0.8 nm bandwidth, scan speed of 6 nm/min, and 0.01-mm cylindrical 
fused silica cells. To improve the signal-to-noise ratio, 8 scans are averaged for each 
CD spectrum to give the final data for secondary structure analysis. Enzyme samples 
are dialyzed against 3 x 500 mL of 10 mM sodium phosphate buffer, pH 7.4, 140 
mM NaF using Slide-A-Lyzer dialysis cassettes at 4 °C. Buffer is changed after 
dialyzing for at least 5 h. The dialysis membrane has 10,000 MW cut-off (Pierce, 
Rockford, IL). Final enzyme concentrations are 1.9 x  10-5, 5.5 x 10~5, and 7.0 x  10~5 
M for wild type, Glu217Ala, and His238AIa, respectively. All CD spectra are 
collected at 25 °C. Percentages of a-helix, P-sheet, P-tum, and random coil in the
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three-dimensional protein structure are estimated using the CCA analysis program 
kindly provided by Professor. G. D. Fasman (Perczel et al., 1992a).
The convex constraint algorithm is a general deconvolution method for 
analyzing a set of CD spectra simultaneously and extracting the secondary structural 
features for all of them. The set o f CD spectra of N proteins are stored in the 
columns of the A[LxN] m atrix, where L is the number o f wavelengths. 
Deconvolution of the A[LxN] matrix results in P pure secondary structure spectra 
stored in the B[LxP] matrix and a conformational weight matrix C[PxN], which 
determines the percentage o f each secondary structure spectrum in the CD spectra 
stored in the A[LxN] matrix.
The A[LxN] matrix provided with the program contains the CD spectra of 30 
proteins whose X-ray structures are known. The CD spectrum of adenosine 
deaminase is added to this 30-protein reference data set and the enlarged 31-protein 
data set is analyzed in the CCA program. The last column of the conformational 
weight C[PxN] matrix contains the secondary structural percentages of adenosine 
deaminase. The product of the B[LxN] and C[PxN] matrices reconstructs a D[LxN] 
matrix at each iteration. The overall similarity of the reconstructed spectra in the 
D[LxN] matrix to the original spectra in the A[LxN] matrix is judged from the a  
value.
where i is the row number denoting wavelength and j is the column number of a
A[LxN] = B[LxP]*C[PxN] = D[LxN] (2)
a 2 = (Zi=i,L Sj=i,N [A(i,j)2 - D(i,j)2])/(LN) (3)
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protein spectrum in the A[LxN] and D[LxN] matrices. The C[PxN] coefficient 
matrix from the iteration with the minimum a  value is then used in a Pearson product 
moment calculation. The coefficient R from  the Pearson product moment 
calculation represents the "similarity" between sets o f pairs o f numbers and 
compares a reference coefficient matrix constructed from X-ray and NMR data with 
the C[PxN] matrix generated by the CCA program. The R value falls in the -1< R 
<+1 range, where +1 represents a perfect similarity.
Stability of wild type and mutant adenosine deaminases to thermal, urea, and 
guanidinium chloride denaturations is determined from the CD at 222 nm recorded 
using a 5 s acquisition time, 0.07 nm bandwidth, and 1.0-mm cylindrical fused silica 
cells. Each data point is an average measured for 2 min in order to improve the 
signal-to-noise ratio. Enzyme concentration is 1.7 x  10*5, 5.8 x  10-5, and 7.3 x 10'5 
M for wild type, G lu217Ala, and His238Ala, respectively. For thermal 
denaturations, molar ellipticity is determined every 5° from 5-95 °C. Urea and 
guanidinium chloride denaturation is measured at 25 °C. Denaturation curves are 
analyzed using the sloping baseline method (Becktel & Schellman, 1987). 
Thermodynamic constants are calculated assuming a two-state unfolding transition.
K = [denatured enzyme]/[native enzyme] (4)
AG° = -RTlnK (5)
AH0 = RT201nK/3T)P (6)
Binding C onstants. Fluorescence m easurem ents are done at room
temperature on an SLM 8000C™ spectrofluorometer. The excitation and emission 
slits are set at 4 nm. Fluorescence intensity is collected in the photon-counting ratio 
mode. 4 x  10-mm cells are used for all fluorescence measurements. The
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fluorescence quantum yield of 2-aminopurine riboside in water is measured relative 
to tryptophan in water, assuming a quantum yield for tryptophan o f 0.14. Binding of 
2-aminopurine riboside to adenosine deaminase is monitored by fluorescence. In 
titration experiments, 2-aminopurine riboside concentration is fixed at 18 |iM, which 
gives an absorbance < 0.08 (10-mm path length) at 320 nm excitation wavelength. 
Small aliquots o f  adenosine deaminase are added to final concentrations of 5-100 
|iM. Relative fluorescence intensities are monitored at 370 nm emission wavelength 
and corrected for background fluorescence and dilution (Birdsall et al., 1983; Harris 
& Bashford, 1987). The equilibrium dissociation constant o f 2-aminopurine riboside 
is determined from the fluorescence data as follows
[ ADA]/(AI/AImax) = Kd/( 1 - AI/AImax) + [2-APr]0 (7)
where Al = I - IQ; AImax = Imax - lo! Io is the fluorescence intensity in the absence of 
adenosine deaminase; Imax is the fluorescence intensity of 2-aminopurine riboside 
when it is saturated by the enzyme; [2-APr]0 is the total concentration of 
2-aminopurine riboside. Imax is obtained from the intercept of a double reciprocal 
plot of 1/1 vs 1/[ADA]. Kd is determined from the slope of a plot of 
[ADA]/(AI/AImax) vs 1/Q -A I/A W ).
Purine riboside is another competitive inhibitor o f adenosine deaminase. 
Since it is not fluorescent, the dissociation constant of purine riboside is determined 
in a competition experiment from 2-aminopurine riboside fluorescence data. Both
2-aminopurine riboside and adenosine deaminase concentrations are fixed such that 
the enzyme is about 70% saturated with 2-aminopurine riboside. 2-aminopurine 
riboside concentration is 22 p.M; enzyme concentration is 3.2, 5.5, and 6.2 p.M for 
wild type, Glu217Ala, and His238Ala, respectively. Small aliquots of purine
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riboside are added to the mixture to final concentrations of 2-120 (iM. The addition 
o f purine riboside displaces 2-aminopurine riboside, which increases the 
fluorescence intensity at 370 nm (Harris & Bashford, 1987). The dissociation 
constant for the competitive inhibitor is determined by
AImax/AI = 1 + (Kd/[2-APr]0)( 1 + [PR]o/Kj) (8)
where FQj is the dissociation constant o f 2-aminopurine riboside; [PR]0 is the total 
concentration o f purine riboside, and K; is the dissociation constant o f purine 
riboside. A plot o f AImax/AI vs [PR]0 yields a straight line, with intercept 
[l+(Kd/[2-APr]0)] and slope (Kd/[2-APr]0) (1/K;) (Harris & Bashford, 1987).
Enzyme Kinetics. Reactant adenosine and product inosine of adenosine 
deaminase-catalyzed reaction are monitored by UV spectrometry or HPLC. All 
measurements are done at room temperature in 10 mM sodium phosphate buffer, pH 
7.4, 140 mM NaCl. The enzyme concentrations in these assays are 8.0 x  10~10 M, 
1.2 x 10’6 M, and 8.5 x  10*7 M for wild-type, Glu217Ala, and His238Ala enzymes, 
respectively. Protein concentration is determined using the Bio-Rad protein 
microassay (Hercules, CA). Six 1 mL reaction mixtures were prepared with 
adenosine concentrations o f 5-40 |iM. In the spectrophotometric assay, the decrease 
o f absorbance at 265 nm (Aea-i = 7.7 x  103 c m ^ M '1) is monitored as a function of 
time in 10-mm cell in a Model 118DS AVIV Associates spectrophotometer. Initial 
velocities are determined from the slope of the absorbance trace (Kalckar, 1947; 
Agarwal & Parks, 1978; Cercignani, 1987). In the HPLC assay, 40 |iL  aliquots are 
removed from the reaction mixture at different times and placed in Eppendorf tubes 
in a water bath at 90 °C to stop the reaction. 20 jiL  aliquots are injected into a 
Rainin HPLC with a Rainin Microsorb-MV C18 column and an ISCO UV
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absorption detector. The column is eluted with a gradient o f 20-80 % buffer A in 15 
min. Buffer A is 95% 50 mM NaH2 PC>4 + 5% methanol and buffer B is 50% 50 mM 
N aH 2 PC>4 + 50% methanol. Inosine and adenosine elute at about 4 and 6 min, 
respectively, with baseline separation at 256 nm. Concentrations of adenosine and 
inosine are calculated from ratios of peak areas and ratios o f extinction coefficients. 
Kinetic constants Km and kcsl are determined from Lineweaver-Burk plots,
l/vj = 1/Vmax + KM/(Vmax [S]) (9)
kcat =  V max/[ET] (10)
where v; is the initial velocity, [S] is total adenosine concentration, and [Et ] is total 
adenosine deaminase concentration. All the kinetic constants are average values for
3-4 separate enzyme preparations.
Results and Conclusion
Secondary Structure. The CD spectra of wild-type and mutant adenosine 
deaminases show two negative bands near 208 and 222 nm and a stronger positive 
band near 190 nm, typical o f a-helical structure (Figure 2.1). Both mutants give less 
intense signals at those positive and negative bands. The magnitude of the molar 
ellipticity at 222 nm for Glu217Ala and His238Ala decreases about 22% and 38%, 
respectively, compared to wild-type enzyme. The decrease o f ellipticity at these 
wavelengths indicates loss o f a-helical structure in the mutants. Therefore, the 
conformational changes in the mutants are quantified by extracting the percentages 
o f different secondary structures o f  wild-type and mutant human adenosine 
deaminases from the CD spectra.
The analysis of CD data is based on reference spectra o f proteins with known 
structures. The convex constraint algorithm (Perczel et al., 1989; Perczel et al.,
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Figure 2.1. Circular dichroism spectra of human adenosine deaminases at 25 °C. (a)
Wild-type enzyme (— ) native, (.... ) CCA fit o f native spectrum, and (— ) renatured
after thermal denaturation. (b) Mutant enzymes (— ) Glu217Ala, (-----) CCA Fit of
Glu217Ala spectrum, (-...... ) His238Ala, and (..... ) CCA fit of His238Ala spectrum.
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1991b; Perczel et al., 1992a) operates on a collection of spectral data to extract the 
operates on a collection of spectral data to extract the common spectral components 
(a-helice, p-sheet, P-tums, etc.) with their spectral weights. These derived "pure" 
CD curves can reconstruct the original data set with great accuracy. As a way of 
overcoming the bias composition o f the database, the CCA analysis varies the 
number o f components P. Recent studies have demonstrated the success o f this 
method in the secondary structure determination of natural and synthetic peptides 
and proteins (Perczel et al., 1991a; Hollosi et al., 1992; Park et al., 1992; Perczel & 
Fasman, 1992; Perczel et al., 1992b; Perczel et al., 1993). There are two 
complementary steps in evaluating the deconvolution results: (1) determination of 
the number o f components and (2) assignment o f the component spectra to specific 
secondary structures.
The program is run with various values of the number of components P. 
Because a run with more components would naturally have a higher probability of 
regeneration o f the original data matrix, the standard deviation cr should decrease as 
P increases. The rate of change of a  with increasing P decreases exponentially with 
inflection and insignificantly after the inflection point. In the analysis of wild-type 
and mutant adenosine deaminases, the inflection point occurs at four components 
with c  = 410 deg cm2 dmoH. Analyses with P = 3 and 5 give a  = 830 and 360 deg 
cm 2 d m o l'1, respectively. Four component spectra are consistent with the X-ray 
crystal structure of mouse adenosine deaminase, which contains a-helix, P-sheet, P 
turns, and random conformations. The "pure" component spectra o f wild-type and 
mutant adenosine deaminases obtained from the CCA program for the P = 4 analysis 
have the following characteristics. The a-helix spectrum has a positive peak at 192 
nm (n-n* transition), with molar ellipticity o f 67,000 to 72,000 deg cm2 dm oH  and 
two negative peaks at 208 (rc-7t* transition) and 222 (n-7t* transition) nm of -34,000
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to -37,000 deg cm2 dmol*1. The (3-sheet spectrum has a positive peak around 197 nm 
(ji—k* transition) of 43,000 to 46,000 deg cm2 dmol*1, and a negative peak at 216 nm 
(n- Jt* transition) o f -14,000 to -17,000 deg cm2 dmol*1. The (3-turn spectrum 
resembles that o f the a-helix only with smaller molar ellipticities (39,000 to 41,000 
deg cm2 dmol*1 at 192 nm, -8,000 to -9,000 deg cm2 dmol*1 at 208 and 222 nm). 
The random conformation has a large negative band around 200 nm of -18,000 to 
-19,000 deg cm2 dmol*1 and a small positive peak at 220 nm of 550 to 610 deg cm2 
dmol*1.
The secondary structural percentages obtained from the coefficients in the 
weight matrices C[PxN] for wild-type and mutant human adenosine deaminases, as 
well as the respective Pearson product moment coefficients R, are summarized in 
Table 2.1. The secondary structural percentages o f mouse adenosine deaminase 
computed from the X-ray structure are also listed for comparison. Wild-type human 
enzyme has similar but slightly higher percentages o f a-helix and (3-sheet than the 
mouse enzyme. While a-helical structure is partially lost in the active-site mutants 
of the human enzyme, Glu217Ala and His238Ala, the P-sheet structure seems to be 
completely intact. The values of the Pearson product moment coefficient R for the 
CCA analyses o f wild-type, Glu217Ala, and His238Ala adenosine deaminases are 
0.86, 0.73, and 0.76, respectively, showing very good agreement between the 
secondary structural percentages obtained from CD and X-ray data o f the 30 
reference proteins. Human adenosine deaminase has 11 more amino acid residues at 
the C-terminus than mouse adenosine deaminase. Assuming that the C-terminal tail 
of human adenosine deaminase is fully a-helical, 3% of the a-helical structure 
would come from the extra tail. Subtracting a 3% contribution from the tail gives 
48% a-helical structure for wild-type human adenosine deaminase, which is very
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Table 2.1. Secondary structure percentages of human adenosine deaminases predicted from CD spectra using convex 
constraint algorithm method.
enzyme a-helix P-sheet p-turns random coil Rp
wild-type 51 ± 2 13 ± 1 11 ± 2 25 ± 2 0.86
Glu217Ala 35 ± 2 15 ± 2 8 ± 2 42 ± 2 0.73
His238Ala 27 ± 1 14 ± 2 6 ± 3 53 ± 2 0.76
mouse wild-type“ 46 11 15 28
“Wilson et al., 1991; 1993.
U>Q\
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close to the 46% a-helical structure for the mouse enzyme. The active-site mutants 
Glu217Ala and His238Ala have lost 33% and 50% of their a-helical structures 
compared to wild type human enzyme. The a-helical regions in the X-ray structure 
of mouse adenosine deaminase comprise the outside of the (3 barrel and the lid on the 
top o f the barrel. The active site itself is situated in the bottom of the barrel. The 
P-sheet structure is preserved in the mutant enzymes, suggesting that the active site is 
largely extant.
Inhibitor B inding. Changes in the enzyme active site pocket upon 
substitution of Glu217 and His238 are examined by inhibitor binding studies (Figure 
2.2). 2-aminopurine riboside is a transition-state analog o f the adenosine substrate; it 
is a fluorescent competitive inhibitor of adenosine deaminase (Kurz et al., 1992). It 
has a fluorescence quantum yield of 0.65 in aqueous solution with an emission 
maximum at about 370 nm. The fluorescence is quenched 60% upon binding of 
adenosine deaminase (Table 2.2). The binding constants of 2-aminopurine riboside 
and purine riboside to wild-type and mutant human adenosine deaminases are 
determined by a fluorescent assay (Table 2.2). The dissociation constants Kd of
2-aminopurine riboside and purine riboside are 2 (lM for the wild-type enzyme. The 
kinetic constants of the wild-type and mutant enzymes are determined by two 
methods with adenosine as substrate: UV spectrometry (Kalckar, 1947; Agarwal & 
Parks, 1978; Cercignani, 1987) and HPLC. Table 2.3 gives the results along with 
literature values from a radiochemical assay using [14C] adenosine (Coleman & 
Hutton, 1975; Bhaumik et al., 1993). The inhibition constants K, of wild-type 
enzyme are determined for 2-aminopurine riboside and purine riboside by UV 
spectrometry. The K; values are identical to the Kd values (Table 2.2). Wild-type 
human adenosine deaminase appears to have 2- to 4-fold higher affinity for purine 
riboside than the wild-type enzymes from calf intestine (Kurz et al., 1992) and
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Table 2.2. Dissociation and inhibition constants (pM) of 2-aminopurine riboside and purine riboside.
inhibitor wild-type Glu217Ala His238Ala
2-aminopurine riboside
% Almax/Io 60.2 ± 0.8 58.8 ±0 .7 57.8 ± 0 .8
Kd(|iM ) 1.7 ±0.3 3.9 ±0 .5 5.7 ± 0 .6
Kj (pM) 1.9 ±0.3 ND° ND«
purine riboside
Kd (pM) 2.3 ± 0 .4 2.9 ± 0 .6 4.6 ± 0.6
Ki (pM) 2.1 ±0 .5 NDa NDa
aNot determined.
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Table 2.3. Kinetic constants of human adenosine deaminases.
enzyme assay wild-type Glu217Ala His238Ala
HPLC
Km (|iM) 23 ± 4 12 ± 3 6.9 ±  0.5
fccat (sec-1) 331 ± 3 0.020 ±0.001 0.1 ±0.003
UV spectrometry
Km (l^M) 20 ± 3 11 ± 4 5.4 ± 0 .3
fccat ( s e c 1) 308 ± 5 0.02 ±0.001 0.1 ±0.003
radiochemical0
Km (HM) 27 ± 4 18.5 ± 3 .4 8.0 ± 0.5
kcat ( s e c 1) 320 0.03 0.1
°Bhaumik et al., 1993.
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mouse (Mohamedali et al., 1996), respectively. It binds 2-aminopurine riboside with 
the same affinity as the wild-type calf enzyme (Kurz et al., 1992). However, the Km 
values of all these wild-type enzymes for adenosine substrate are the same: human 
Km = 22 ± 4  jiM  (Table 3), calf Km =19 jiM (Kurz et al., 1992), and mouse Km = 19 
± 4 jiM (Mohamedali et al., 1996).
The Glu217Ala mutant of human adenosine deaminase binds purine riboside 
with the same affinity as wild-type enzyme. However, the binding affinity for
2-aminopurine riboside is decreased 2-fold in the mutant compared to wild-type. 
The His238Ala mutant, on the other hand, gives consistently larger K<j values for 
both purine riboside and 2-aminopurine riboside, binding the inhibitors with 2- to
3-fold lower affinity than wild-type enzyme. The wild-type and mutant adenosine 
deaminases quench 2-aminopurine riboside fluorescence to the same extent (less than 
3% difference), suggesting that the inhibitor binding sites are similar. These results 
suggest that the binding determinants in the enzyme active site are only slightly 
disturbed by the Glu217 and His238 mutations, despite substantial loss o f a-helical 
structure in the mutant enzymes. A series of mutants with Glu217 replaced by Asp, 
Gly, Gin, and Ser have been made in mouse adenosine deaminase (Mohamedali et 
al., 1996). In the mouse enzyme, the inhibition constant K; for purine riboside is also 
not changed by substitution at Glu217.
The Kd values of the human adenosine deaminase mutants indicate slightly 
decreased inhibitor binding affinities with wild-type > Glu217Ala > His238Ala. 
Previous kinetic studies using a radiochemical assay, however, show smaller Km 
values for these mutants than for the wild-type enzyme (Bhaumik et al., 1993), 
suggesting that the mutants have higher affinity for substrate with His238Ala > 
Glu217Ala > wild-type. We measured the kinetic constants for several different 
enzyme preparations o f wild-type and mutant human adenosine deaminases by two
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different assays, UV spectrometry and HPLC, and confirmed the lower Km values 
for the mutant enzymes. The Michaelis constant Km equals the dissociation constant 
IQ when the rate of dissociation of enzyme-substrate complex is much faster than the 
catalytic rate Q at. The kcat values are decreased 15- and 3.2- thousandfold for the 
Glu217Ala and His238Ala mutants, respectively, compared to the wild-type fccat 
(Table 2.3). In principle, Km values should be better approximations o f IQ  in the 
mutants than in the wild-type enzyme. The inverse order o f binding affinity for 
substrate and transition-state analog inhibitors in the wild-type and mutant adenosine 
deaminases invites comment. First, the Km values for mutant adenosine deaminases 
may be inaccurate due to the difficulty of measuring very low levels of enzyme 
activity. This seems unlikely in view of the good agreement in the results from 
different assay methods. Second, the Ala substitutions in the active site may 
improve substrate binding, while weakening inhibitor binding. Third, Glu217Ala 
has the same affinity for purine riboside as the wild-type enzyme. If the affinity for 
substrate were also the same in the two enzymes, then the Km value of Glu217Ala 
would provide a better estimate of IQ than the wild-type Km value. Fourth, the 
binding determinants for substrate and inhibitors may be different. However, the 
substrate and inhibitor binding affinities in the His238Ala mutant are almost the 
same, which implies that the binding determinants for these compounds are similar.
Mohamedali et al. (1996) report that wild-type and Glu217 mutant mouse 
adenosine deaminases lost enzyme activity upon storage in phosphate buffer. 
Therefore, both wild-type and mutant mouse enzymes were purified in the presence 
of exogenous Zn and stored in Tris buffer containing 10 |iM  Zn2+. We find no 
evidence for loss of Zn from wild-type or mutant human adenosine deaminases 
(Bhaumik et al., 1993). First, Zn determination using flame atomic absorption 
spectrometry demonstrated that wild-type, Glu217Ala, and His238Ala human
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adenosine deaminases contain one mol of Zn2+ per mol of protein. Graphite furnace 
atomic absorption gave 2 mol o f Zn2+ per mol of protein, purportedly due to 
inaccuracies in Zn2+ determinations on small quantities o f  protein. Second, 
phosphate buffer was replaced with Tris buffer in the enzyme purifications. 
Wild-type and mutant adenosine deaminases were purified in the absence and 
presence of exogenous Zn2+. The use o f a non-Zn-chelating buffer containing 
exogenous Zn resulted in a very small (0.05-0.12%) increase in wild-type enzyme 
activity, but did not increase Glu217Ala or His238Ala mutant activity. Third, 
wild-type, Glu217Ala, and His238Ala adenosine deaminases were purified in a one- 
step procedure on a monoclonal antibody column eluted with 4-6 M urea. A 
two-column purification procedure on DEAE-Sephadex and adenosine- or purine 
riboside-Sepharose was also used for comparison. Neither wild-type nor the two 
mutants exhibit differential enzyme specific activities due to purification method. 
Thus, in the case o f human adenosine deaminase, the wild-type and mutant enzymes 
in phosphate buffer have a Zn molecule in the active site. Perhaps the human 
enzyme binds Zn more tightly than the mouse enzyme.
Protein Stability. The sizable changes in secondary structure of the mutant 
human adenosine deaminases have no effect on Zn binding and only modest effects 
on substrate and inhibitor binding in the enzyme active site. This strongly suggests 
that replacement of key amino acid functional groups, not the structural changes, is 
responsible for the dramatic loss in enzyme activity. This raises a question about the 
role o f the fraction of a-helical structure in adenosine deaminase that is lost in the 
mutant enzymes. A simple way to examine the effect of specific amino acids on 
protein structure is to compare the stability of wild-type and mutant proteins. We 
therefore measure the relative stabilities o f wild-type, GIu217Ala, and His238Ala 
human adenosine deam inases to thermal, urea, and guanidinium  chloride
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denaturation by monitoring the CD at 222 nm. O f the two negative a-helix  CD 
bands, 222 nm avoids the significant UV absorption of urea and guanidinium 
chloride below 210 nm wavelength. The baseline dependencies o f CD signals on 
temperature and denaturant concentrations are linear with fairly small slope (<0.2%).
The denaturation profiles are analyzed assuming a two-state reversible 
transition, in which only the native and fully-denatured conformational states are 
substantially populated and the partially  folded interm ediate states are 
thermodynamically unstable. The thermal denaturation curves for wild-type and 
mutant human adenosine deaminases show a single-step pattern (Figure 2.3), 
indicating a two-state transition (Pace, 1986). The cooperative melting transition of 
wild-type enzyme is 92% reversible, as judged from the CD spectrum after slow 
cooling (Figure 2.1). Two-state transition curves are also obtained upon urea and 
guanidinium chloride denaturation (Figures 2.4 and 2.5). The urea denaturation is 
reversible. One of the two methods used to purify the protein involves treatment 
with 4-6 M urea (Bhaumik et al., 1993). None of the enzymes exhibit differential 
specific activities in the two purification methods, indicating that the enzymes are 
fully refolded after removal of urea. Addition of 20 p.M Zn2+ during urea treatment 
changes neither the magnitudes of the molar ellipticities nor the denaturation profiles 
for wild-type and mutant enzymes. The denaturation curves of all three unfolding 
processes for wild-type, Glu217Ala, and His238Ala adenosine deaminases are 
quantitatively fit to the two-state constant ACp or AG models described previously 
(Schellman et al., 1981; Pace, 1986).
Wild-type adenosine deaminase has a high melting temperature Tm of 70 °C, 
making it very stable with respect to thermal denaturation. The mutants are also 
quite heat resistant, but not as stable as wild-type enzyme (Figure 2.3). Glu217Ala is 
more stable than His238Ala; the melting temperatures are 65 and 60 °C,
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respectively. Thermodynamic constants for thermal unfolding are calculated from 
the Van't Hoff equation. The enthalpy change for the transition is obtained from eq 6 
(Table 2.4). The enthalpy changes for thermal denaturation o f adenosine deaminases 
are positive, with AH(wt) > AH(GIu2I7AIa) > AH(His238Ala).
Urea denaturation reactions are monitored at 25 °C. The Gibbs free energy 
of protein unfolding, AG, is calculated from eq 5. For a two-state transition, AG 
varies linearly with denaturant concentration (Pace, 1986). The data are fit by linear 
regression to the following equation:
AG = AG(H20) + k [denaturant] (11)
where AG(H2 0 ) is the free energy of protein unfolding in the absence of denaturant 
and k is a measure o f dependence of AG on denaturant concentration. The 
concentrations at the denaturation midpoint Cm of wild-type, GIu217Ala, and 
His238Ala are 5.3, 4.2, and 3.7 M urea, respectively (Figure 2.4). All AG(H20) 
values are positive (Table 2.4): AG(wt) > AG(Glu217Ala) > AG(His238Ala). The 
relative stabilities of wild-type and mutant enzymes to thermal and urea denaturation 
are the same.
Both wild-type and mutant human adenosine deaminases begin to unfold at 
very low concentrations of guanidinium chloride (<0.2 M). Wild-type, Glu217Ala, 
and His238Ala seem to show different denaturation profiles, though all appear to be 
single-step processes. For Glu217Ala the unfolding transition appears somewhat 
less cooperative than for wild-type and His238Ala. The molar ellipticity changes of 
wild-type enzyme have a midpoint at about 1.2 M and a total loss o f secondary 
structure above 1.5 M guanidinium chloride (Figure 2.5). The midpoints for 
Glu217Ala and His238Ala mutants are l . l  and 0.4 M, respectively. The AG values
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are fit to eq 11 assuming a two-state transition for all three proteins in guanidinium 
chloride. All AG(H20) values are positive (Table 2.4), but the order is different: 
AG(Glu217Ala) = AG(wt) > AG(His238Ala). Although the Glu217Ala mutant gives 
a slightly higher AG(H2 0 ) value than wild-type, the wild-type enzyme has a slightly 
higher midpoint for denaturation. The sloping baseline method used here for 
calculation of AG involves the extrapolation o f pre- and post-transition regions, 
which underestimates the error in the parameters determined because no error is 
assumed for the pre- and post-transition baselines (Santoro & Bolen, 1988). Possibly 
that accounts for the inverse order of Cm and AG(H2 0 ) values for the wild-type and 
Glu217Ala mutant. The stability o f wild-type and Glu217Ala to guanidinium 
chloride denaturation is about the same.
The estimates of AG(H20) of wild-type, Glu217Ala, and His238Ala human 
adenosine deaminases derived from guanidinium chloride unfolding experiments are 
greater than those from the urea unfolding experiments, which result from stronger 
binding of guanidinium chloride to the folded proteins. Also, the molar ellipticities 
of the final unfolded states for urea (about -4,200 deg cm2 dm ol'1) and guanidinium 
chloride (about -5,800 deg cm2 dmol*1) denaturation are different, indicating that the 
unfolded states of the proteins in urea and guanidinium chloride solutions may differ 
significantly in the extent o f interaction with denaturant. The ellipticity for thermal 
denaturation plateau is -5 ,000 deg cm2 dm ol'1. The final unfolded states for the 
three proteins appear to approach almost the same plateau value in each solvent, 
indicating that the wild-type and mutant enzymes reach the same unfolded state in 
each denaturation process. The relatively m inor differences among molar 
ellipticities of unfolded states of wild-type and mutant adenosine deaminases in each 
denaturation process are within experimental error (±1,000 deg cm2 dmol'1).
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Table 2.4. Thermodynamic constants for human adenosine deaminases.
denaturant wild-type Glu217Ala His238Ala
thermal
AH (kJ/mol) 340 ± 2 335 ± 3 330 ± 3
AAH (kJ/mol) 0 5 10
Tm (°C) 70 ± 1 65 ± 1 60 ± 1
urea
AG(H20) (kJ/mol) 23 ± 1 12 ± 1 3 ± 1
AAG (kJ/mol) 0 11 20
Cm (M) 5.3 ±0 .2 4.2 ± 0.2 3.7 ±0.3
guanidinium chloride
AG(H20) (kJ/mol) 17 ± 2 19 ± 3 11 ± 3
AAG (kJ/mol) 0 -2 6
Cm (M) 1.2 ± 0.1 1.1 ±0.1 0.4 ±0.1
O
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Further Discussions. Human adenosine deaminase shows extensive overall 
sequence similarity (83% identical residues in the first 352 amino acids) with its 
mouse counterpart (Chang et al., 1991). The two enzymes have identical residues 
directly or indirectly involved in inhibitor binding. The X-ray crystal structure of 
mouse adenosine deaminase contains a parallel a/p-barrel motif with eight central P- 
sheet strands and eight peripheral a  helices (Wilson et al., 1991; Sharff et al., 1992; 
Wilson & Quiocho, 1993). The enzyme also has five additional a-helices outside the 
barrel: H I, H2; H3 between p i and a l ;  and H4 and H5 after a8 . The adenosine 
deaminase barrel has a "lid" structure on the top with the Zn buried at the bottom. 
The lid is composed of two parts: H3 a-helix on one side and a loop between P3 and 
a3 on the other side.
From the crystal structure of mouse adenosine deaminase, it is not obvious 
why replacement o f Glu2I7 and His238 should cause loss of a-helical structure. 
Glu217 is located in the loop between P5 and a 5  o f the a/p-barrel and its carboxyl 
group is roughly coplanar with the inhibitor bound at the active site. Apart from its 
function o f donating a proton to the 1 position of the purine ring, Glu217 is 
structurally linked with two a  helices. The carboxyl side chain is within van der 
Waals distance o f three amino acids in the C-terminal end of a5  as well as o f  three 
amino acids in the loop lid. Additionally, Glu217 is within 5 A of three amino acids 
in the H3 a-helical lid of the active site. His238 is the last of three residues in p6 of 
the barrel. The imidazole ring is within van der Waals distance of four amino acids 
in a6  as well as three amino acids in a8 and H4 a  helices. His238 is also within 6 A 
of the H3 a-helical and loop lids of the barrel. In the cases of Glu217Ala and 
His238Ala mutants, the loss of a-helical structure may come in part from helices 
external to the a /p  barrel, which account for about 40% of the a-helical structure of 
adenosine deaminase. This would rationalize our finding that the conformational
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
changes in the mutants destabilize the protein with only minor affects on ligand 
binding. On the other hand, the ligand binding determinants are all on P-sheets or 
turns: (31, (35, p8; turns between p i and HI, P2 and a2. It is possible that the barrel 
remains intact with some of the outside helices disordered.
The binding constants for purine riboside and 2-aminopurine riboside to 
wild-type adenosine deaminase are apparent binding constants (Jones et al., 1989). 
These inhibitors are unhydrated in solution, but are immediately hydrated in the 
enzyme active site to form the respective 1,6-dihydropurine riboside (Kurz et al.,
1992). The GIu217 mutants of mouse adenosine deaminase do not hydrate purine 
riboside to form the tetrahedral intermediate that occurs in the wild-type 
enzyme-inhibitor complex (Mohamedali et al., 1996). The Glu217Ala mutant of 
human adenosine deaminase is thus not expected to form the hydrate. The mutant 
enzyme binds the unhydrated purine riboside and 2-aminopurine riboside in a single 
step to give a true binding constant for a ground-state analog inhibitor. The 
His238Ala mutant lacks the proposed proton acceptor for the incoming hydroxyl that 
hydrates purine riboside in the enzyme active site (Wilson & Quiocho, 1993). This 
mutant is not expected to form the tetrahedral intermediate efficiently, so the 
observed binding constants for purine riboside and 2-aminopurine riboside could 
likewise be considered true binding constants of ground-state inhibitors.
Inherited deficiency of adenosine deaminase accounts for about one-fourth of 
SCID in humans. DNA sequences have been reported for the defective adenosine 
deaminase genes from six cell lines derived from SCID patients (Bonthron et al., 
1985; Valerio et al., 1986; Akeson et al., 1987; Akeson et al., 1988; Hirschhom et 
al., 1989). The lack of adenosine deaminase protein is the reason for the enzyme 
deficiency in the patients. Normal levels of mutated mRNA are present in the cells, 
but the proteins are rapidly degraded after translation. None of these defective
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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human adenosine deaminases are active site mutants: four of the substituted amino 
acids are buried residues and two are surface residues (Wilson et al., 1991). In the 
Glu217Ala and His238Ala mutants, the loss o f a-helical structure destablizes the 
proteins and makes them more susceptible to degradation by proteases in the 
baculovirus expression system. The yields o f Glu217Ala and His238Ala are 30 and 
15%, respectively, of the wild-type enzyme as isolated by two different protein 
purification methods (Medin et al., 1990; Bhaumik et al., 1993). Thus, substitutions 
o f amino acids in the active site as well as elsewhere in adenosine deaminase 
apparently have profound effects on enzyme structure and stability.
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CHAPTER 3: ZN-BINDING LIGANDS AT THE ACTIVE SITE OF HUMAN 
ADENOSINE DEAMINASE: AN EXAFS INVESTIGATION
Introduction
Human adenosine deaminase is a ubiquitous Zn metalloenzyme that catalyzes 
the irreversible hydrolytic deamination of adenosine and deoxyadenosine to produce 
inosine and deoxyinosine, respectively, as part o f the purine salvage pathway. 
Adenosine deam inase is found on the surface and in the cytoplasm  of 
microorganisms and mammalian cells in several molecular and electrophoretic forms 
(Spencer et al., 1968; Edwards et al., 1971; Akedo et al., 1972; Osbome & Spencer, 
1973; Hirschhom, 1975; Schrader et al., 1976; Van der Weyden & Kelly, 1976; 
Carson et al., 1977; Daddona & Kelly, 1977; Schrader & Stacy, 1977; Wiginton 
et al., 1981).
The X-ray crystal structures o f mouse adenosine deaminase have been 
determ ined fo r com plexes w ith a transition -sta te  analog  inh ib ito r 
6(R)-hydroxyl-l,6-dihydropurine riboside (Wilson et al., 1991; Sharff et al., 1992), a 
ground-state analog inhibitor 1-deazaadenosine (Wilson & Quiocho, 1993), and 
product inosine (Wilson & Quiocho, 1994). The core of the enzyme is constructed 
with eight (3 strands connected by eight peripheral a  helices, to form a parallel 
a/p-barrel motif. The structure also has five additional a  helices, three located 
between P 1 and a l  and two al the C-terminus. The catalytic site is located at the 
carboxy end o f the P-barrel inside the pocket. The narrow opening o f the pocket is 
partially capped by a loop on one side and an a  helix on the opposite side. The 
crystal structure also reveals the presence of an active-site Zn, which lies in the 
deepest part of the pocket at the carboxy end of the P barrel. The Zn is coordinated 
by five atoms: three N82 atoms from His 15, Hisl7, and His214, one 08 2  atom from
57
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Asp295, and the 0 6  atom from the transition-state analog HDPR or a hydroxide (or 
water) O in the case of ADA-DAA complex. The presence o f an axial hydroxyl 
covalently bonded to C-6 of purine riboside in ADA-HDPR complex confirms the 
tetrahedral intermediate observed by 13C NMR (Wilson & Quiocho, 1994).
A new enzyme catalytic mechanism was therefore proposed based on the 
crystal structures of mouse adenosine deaminase, in which Zn plays a crucial role by 
facilitating formation of a pre-transition state with a bound activated water molecule 
or a hydroxide (Wilson & Quiocho, 1993). In this mechanism, Glu217 donates a 
proton to N1 of substrate adenosine, thereby reducing the N1-C6 double bond 
character and rendering C6 susceptible to nucleophilic attack and transformation 
from sp2 to sp3 in the tetrahedral adduct. A Zn-activated water or hydroxide is the 
attacking nucleophile. His238 acts as a general base/acid and plays an important role 
in enzyme catalysis. Activation o f the water involves coordination o f the oxygen to 
the powerful Zn electrophile, donation of one hydrogen to a hydrogen bond with 051 
of Asp295, and donation of the other hydrogen to a hydrogen bond with Ne2 of 
His238. The abstracted proton on Ne2 of His238 attacks the N6 amino leaving 
group.
Human adenosine deaminase has 11 additional amino acids at the C-terminus 
and 83% homology with the mouse enzyme in the rest o f the sequence with 
completely conserved active-site amino acid residues. Active-site amino acids 
Glu217 and His238 were previously substituted with alanine by site-directed 
mutagenesis o f human adenosine deaminase (Medin et al., 1990; Bhaumik et al., 
1993). The active-site mutants Glu217Ala and His238Ala of human enzyme show 
little or no change in Zn content and Km values, yet dramatic loss of enzyme activity 
(Bhaumik et al., 1993; Zeng et al., 1996). Dissociation constants for transition-state 
analog inhibitors 2-aminopurine riboside and purine riboside are similar for
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
59
wild-type and mutant enzymes, suggesting that inhibitor and substrate binding 
determinants are preserved in the mutants (Zeng et al., 1996). I3C NMR shows that 
GIu217 mutants of mouse adenosine deaminase do not hydrate purine riboside to 
form the tetrahedral intermediate HDPR (Mohamedali et al., 1996).
X-ray absorption spectroscopy has become an important quantitative 
experimental technique to examine the intimate environment of specific metal 
centers in a variety of metalloproteins. The extended X-ray absorption fine structure 
provides detailed information on the first coordination shell of the excited metal 
atom: the metal-Iigand distances and the type and coordination number o f  ligands 
(Stern, 1974; Teo, 1980; Lee et al., 1981; Fay et al., 1988; Sharpe, 1990; Gamer, 
1991; Lida, 1991). However, the short-range, single scattering EXAFS has serious 
limitations, especially in the cases of metalloproteins. When atoms (including the 
X-ray absorbing atom and its neighbor) are arranged in a linear or near collinear 
fashion, such as CN- or CO- in imidazole or carboxyl, the forward scattering is 
strongly enhanced and EXAFS contributions from neighboring atoms as far as 8 A 
can be observed (Teo, 1981). The single-scattering theory of EXAFS is not 
applicable in these situations and multiple-scattering processes involving the 
intervening atoms should be taken into account in order to provide accurate 
structural characterization of the ligands bound to the metal center.
EXAFS has proved to be a particularly valuable and direct probe of the 
environment of Zn atoms, since Zn is silent in magnetic resonance and other 
spectroscopic methods (Cramer, 1987). EXAFS studies at the Zn Ka-absorption 
edge of metalloproteins have in recent years contributed to the identification of metal 
ligands in Zn proteins (Sim olo e t al., 1986; Garner & Feiters, 1987; 
Eggers-Borkenstein et al., 1989; Feiters & Jeffery, 1989; Navaratnam et al., 1989; 
Dent et al., 1990; Chance et al., 1992; Zhang et al., 1992; Randall et al., 1993; Zhang
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& Auld, 1993; Bracey e t al., 1994; Rowlett et al., 1994; Thorvaldsen et al., 1994; 
Ball et al., 1995; Liu et al., 1995; Priggemeyer et al., 1995; Garcia et al., 1996). The 
oscillations in the X-ray absorption coefficient after the Zn Ka -edge step are 
described by interference effects on the central absorber Zn atom, due to the fact that 
the photoelectron wave leaving the excited Zn atom is backscattered by the 
Zn-binding ligands (Stem, 1974). Phase-corrected Fourier transformation of the 
EXAFS with respect to exp(-i2xR), where fcis the photoelectron wave vector, and R 
is the absorber-backscatterer distance, gives the radial distribution function around 
the absorber Zn (Sayers et al., 1971). From analysis of the EXAFS, ligand distances 
(short-range, within 4 A) and coordination numbers may be derived with accuracies 
o f ± 0.02 A (Citrin et al., 1976) and 15% (Eisenberger & Lengeler, 1980), 
respectively.
Given the case o f  adenosine deaminase, EXAFS offers a powerful technique 
to address several important questions about the active-site Zn. W hat is the 
coordination sphere of the catalytic Zn of human adenosine deaminase? Are there 
five ligands coordinating the Zn, one of which is an "activated water" as suggested 
by the X-ray structure o f mouse adenosine deaminase? How does the structure 
around the Zn change upon binding of ground- and transition-state analog inhibitors? 
What are the implications of these conformational changes for enzyme catalysis? 
What can structural studies of the active-site Zn in Glu217AIa and His238Ala 
mutants tell us about the functional roles of these amino acid residues in the catalytic 
mechanism? In this paper we present the results of EXAFS of the wild-type and 
mutant human adenosine deaminases and their complexes with ground-state analog 
inhibitor 1-deazaadenosine and transition-state analog inhibitor purine riboside. The 
EXAFS data are analyzed with the Cerius2 program using the curved wave theory 
(Gurman et al., 1984; Gurman et al., 1986) and the small atom theory (Gurman,
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1988) multiple scattering. The X-ray coordinates o f mouse adenosine deaminase 
with bound 1-deazaadenosine or HDPR provide the starting geometry for the 
calculations (Wilson et al., 1991; Wilson & Quiocho, 1993). Zn-ligand coordination 
number and distances are obtained for wild-type and mutant enzymes in the absence 
and presence o f inhibitors. Comparison o f the EXAFS results for the various 
enzyme forms supports the proposed mechanism for adenosine deaminase.
Materials and Methods
Materials. Trichoplusia ni (cabbage looper) larvae infected with recombinant 
baculovirus containing the coding sequence for human adenosine deaminase were 
produced by methods described previously (Medin et al., 1990). Benzamidine, 
phenylmethylsulfonyl fluoride, leupeptin, pepstatin, protamine sulfate, purine 
riboside, and Epoxy Activated Sepharose 6B are purchased from Sigma Chemical 
Co. (St Louis, MO). Ammonium sulfate is ultrapure grade from ICN (Aurora, 
Ohio). DEAE Sephadex A-50 is a Pharm acia (Uppsala, Sweden) product. 
1-deazaadenosine is prepared according to Antonini et al (Antonini et al., 1984). All 
other reagents are of the highest commercial grade. Enzyme stock solutions are 
stored in 50 mM Tris buffer, pH 6.8, 0.15 M NaCl, 40% glycerol (OmniSolv, 
EMScience, Cherryhill, New Jersey) at -20 °C. Concentration ranges and specific 
activities for wild-type, Glu217Ala, and His238Ala stock solutions are 8.4 - 24, 
6.2 - 8.5, and 2.8 - 3.6 x  10‘5 M; and 450, 0.02, and 0.13 units/mg, respectively. 
Protein concentration is determined by the Bradford method and molarity is 
calculated using a molecular weight of 41,000.
Protein Purification . Wild-type human adenosine deaminase is purified by 
adenosine affinity chromatography (Schrader et al., 1976; Medin et al., 1990). 
Glu217Ala and His238Ala mutants are purified by purine riboside affinity 
chromatography (Ogawa et al., 1987; Aran et al., 1990). About 25 g of frozen larvae
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stored at -70 °C are added to 80 mL of extraction buffer containing 10 mM sodium 
acetate, pH 6.4, 10 mM 2-mercaptoethanol along with four protease inhibitors: 5 mM 
benzamidine, 3 mM phenylmethylsulfonyl fluoride, 20 (iM leupeptin, and 8 fiM 
pepstatin. The larvae are homogenized on ice using a Tekmar tissuemizer SDT set at 
medium speed with 3-15 s bursts. The homogenate is treated with 0.104 g of 
protamine sulfate to remove viral DNA that may inhibit the binding o f adenosine 
deaminase to the DEAE-Sephadex column. Subsequent steps are carried out at 4 °C. 
After gentle stirring for 30 min, the homogenate is centrifuged at 15,000 rpm for 30 
min. The supernatant is filtered through four layers o f cheesecloth. The clarified 
supernatant is then diluted with an equal volume of wash buffer consisting of 10 mM 
sodium acetate, pH 6.4, and is applied to a 5 x 10 cm DEAE-Sephadex A-50 column 
(Bio-Rad) pre-equilibrated with wash buffer. The column is washed with 1 L of 
wash buffer and the mutant protein is batch eluted with wash buffer containing 0.5 M 
NaCl. The eluate is brought to 70% saturation with ammonium sulfate and 
centrifuged at 10,000 rpm for 20 min. The ammonium sulfate precipitate is 
resuspended in a minimal volume of 50 mM Tris buffer, pH 6.8, 0.15 M NaCl and 
loaded onto a 1.5 x 60 cm purine riboside Sepharose 6B column equilibrated with 
Tris buffer. The protein is eluted with 50 mM Tris, pH 6.8, 0.15 M NaCl at a flow 
rate of 0.12 mL/min. Approximately 200-5 mL fractions are collected and analyzed 
by SDS-polyacrylamide gel electrophoresis (Laemmli, 1970). Approximately 100 
fractions containing the 41 kDa mutant protein are pooled and concentrated to 0.5-1 
mL by ultrafiltration using an Amicon Model 52. G lycerol is added to the 
concentrated enzyme solution to about 40% v/v. Enzyme activity is measured by a 
radiochemical enzyme assay using 14C-adenosine (Coleman et al., 1978) Protein 
concentration is determined by the Coomassie Brilliant Blue G-250 binding method
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(Bradford, 1976) with bovine serum albumin as standard and protein microassay dye 
reagents purchased from Bio-Rad.
Protein Sample Preparation for EXAFS. 10 mg of wild-type, Glu217Ala, 
and His238Ala human adenosine deaminases are concentrated to 60 (iL at 4 °C using 
M icrocon-10,000 clinical sample concentrators (Amicon) and an Eppendorf 
microfuge. 40 jiL o f ethylene glycol is added to give a final protein concentration of 
about 2.5 mM. The resulting 100 (J.L protein samples are loaded with a Hamilton 
syringe into rectangular lucite cells with a 1 mm path length and Kapton foil 
windows. The EXAFS samples are stored and transported frozen in liquid nitrogen 
prior to EXAFS experiments. No changes in either the near edge or the EXAFS 
region are observed during data collection, which typically lasts about 12-18 h per 
sample, indicating that the X-ray radiation does not seem to cause any significant 
damage to the proteins.
EXAFS. Zn K-edge X-ray absorption spectroscopic data are collected on 
beamline VII-3 at the Stanford Synchrotron Radiation Laboratory for wild-type and 
Glu217Ala mutant adenosine deaminases and on beamline X10-C at the National 
Synchrotron Light Source at Brookhaven National Laboratory for His238Ala mutant. 
X-ray absorption spectra are recorded over the energy range 9500-10400 eV for Zn 
K-edge at 10 K using an Oxford Instruments CF1208 liquid He cryostat. Internal 
photon energy is calibrated by simultaneously collecting a transmission spectrum of 
a Zn foil and assigning its first inflection point energy to 9659.0 eV. On beamline 
VD-3 at SSRL, Zn K-edge X-ray absorption spectra are collected on an unfocused 
multipole wiggler beam under dedicated ring conditions (3.0 GeV, 50-100 mA) 
using a Si(220) double-crystal monochromator. At NSLS, the beamline X10-C is 
run in the focused mode with a Si(l 11) double-crystal monochromator. The typical 
energy resolution o f these monochromators is about 1 eV. The rejection of higher
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order harmonics in the incident beam is accomplished by using a mirror position 
feedback system (Sansone et al., 1991). Incident beam intensity is monitored with a 
nitrogen gas-filled ionization chamber. XAFS data are recorded in the fluorescence 
excitation mode (Jaklevic et al., 1977) using a Canberra Industries 13-element Ge 
solid-state array detector with single channel analyzer windows set on the Zn K<x 
fluorescence signal(Cramer et al., 1988). Copper foils are placed in front of the 
detector to reduce scattered radiation.
X-ray absorption spectra for protein samples are recorded as the ratio F/I, 
where F is fluorescence intensity and I is incident intensity. EXAFS spectra are 
measured with 50 eV steps below the edge (9500-9630 eV), 0.2 eV steps in the edge 
range (9630-9700 eV), and 50 eV steps in the EXAFS range (9700-10400 eV). 
Integration time for each data point varies from 1 s in the pre-edge range to 8 s in the 
edge and EXAFS ranges for a total integration time of approximately 45 min per 
scan. Total exposure time for each protein sample is about 16 h. About 15-20 scans 
are taken for each protein sample, and each scan contains data from 8-10 detector 
channels. The total incident count rate on each detector is maintained at about 
20,000 cps without dead time correction, and an amplifier shaping time of 1 jis is 
used in all measurements. The windowed count rate of Zn K<x fluorescence for each 
protein sample is several hundred cps per channel.
The EXAFS is extracted from the raw X-ray absorption spectra and analyzed 
to yield simulated EXAFS x( k) using EXAFSPAK, a suite of computer programs for 
analysis of X-ray absorption spectra (Cramer et al., 1978; Cramer & Hodgson, 1979; 
Teo, 1981; Scott, 1985). First, all scans are individually plotted and examined to 
confirm the absence of artifacts. Any spectrum showing irregularities is omitted 
from further data processing. Second, the raw XAS are recalibrated using the 
transmission spectrum of the Zn foil standard. Third, 15-20 raw XAS for each
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protein sample are averaged. Fourth, the average XAS is used as input for EXAFS 
data reduction manipulation: (i) Pre-edge background is subtracted by first-order 
polynomial fitting; (ii) Above-edge background is corrected by two-region cubic 
spline fitting; (iii) Average XAS is normalized to one Zn per molecule and converted 
from E space to k  space according to
K — [2me(E-E0)/h2] l/2 = [0.262449(E-Eo)]1/2 (1)
where K is the photoelectron wave vector in A '1, me is electron mass in kg, E is 
photon energy in eV, E0 is threshold energy chosen as the photon energy at 
half-height of the absorption jump, and b. is Planck's constant. The data are weighted 
to k3 space to offset attenuation of the EXAFS signal with increasing photon energy; 
and (iv) The resulting EXAFS are Fourier transformed from energy space to radial 
distance space. The simulated EXAFS is calculated as
X( k)=£{ [NsAs( k:)Sc/( xRas2)]exp(-2 Kr2a as2)exp(-2Ras/>.)sin[2 kR ^  3>as(K)]}
(2 )
where %(k) is EXAFS amplitude function, Ns is the number of scattering atoms 
within a shell, As(k") is the curved-wave back-scattering amplitude of the 
absorber-scatterer pair, Sc is the scaling factor that accounts for the effect of intrinsic 
processes and is specific to the absorber-scatterer pair, a as2 is the mean square 
deviation o f the absorber-scatterer bond length Ras, Q>as(K) is the distance-dependent 
phase shift, and X is the photoelectron mean free-path.
The EXAFS is fitted to three EXAFS phase and amplitude functions to obtain 
protein structural information. The first analysis is based on McKale curved-wave
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single-scattering theory. After the Fourier transform ation over the range of 
k=  2.5-13 A-1, a radial distance R-window of 0.8-3.2 A is applied to filter out the 
multiple-scattering contributions. The filtered Fourier transformed spectra are 
back-transformed to k  space for single-scattering EXAFS curve fitting. The 
goodness o f fit is described by the F factor, which is the sum of squares of the 
differences between experimental and calculated curves.
In addition to the single-scattering term to determine nearest-neighbor 
distances, multiple-scattering contributions are often important in quantitative 
calculations of EXAFS. Especially in cases where the Zn ligands are rigid ring 
structures such as the imidazole ring of histidine or purine ring o f purine riboside and 
1-deazaadenosine, multiple-scattering terms are required for a good fit of the raw 
EXAFS. The Cerius2 multiple-scattering calculation is based on an automated 
implementation of (i) the curved-wave multiple-scattering theory (Gurman et al., 
1984; Gurman et al., 1986; Rehr & Albers, 1990) or the small atom theory (Gurman,
1988), (ii) an efficient method for enumerating multiple-scattering paths, (iii) ab  
initio amplitude functions As(x)exp(-2Ras/^) and phase functions Oas( k) (Mustre de 
Leon et al., 1991; Rehr et al., 1991; Rehr et al., 1992), and (iv) multiple-scattering 
Debye-Waller factors. The calculation has four steps: (i) The scattering potentials, 
phase shifts, dipole matrix elements, and absolute energies are calculated; (ii) The 
scattering paths for the metal cluster are enumerated; (iii) The effective scattering 
amplitudes and other EXAFS parameters are calculated for each scattering path; and 
(iv) The EXAFS parameters from one or more paths are combined to calculate a total 
EXAFS. The geometry information used by Cerius2 is taken from the crystal 
structures o f wild-type mouse adenosine deaminase complexes with HDPR and 
1-deazaadenosine (Wilson et al., 1988; Wilson et al., 1991; Wilson & Quiocho,
1993). The sum in eq 2 is taken over all scattering atoms in a 6 A shell. The curve
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fitting uses k3-weighted data over the 2.5-13 A-1 range with the scaling factor Sc 
fixed at 0.9 and the coordination number Ns fixed at integer values. The 
metal-ligand distances and the Debye-W aller-like factors exp(-2fc2cyas2) are 
adjustable parameters. A nonlinear least-square Marquardt algorithm routine is used 
to minimize the difference between the calculated and observed EXAFS. The 
quality of the fit, the R-factor, is defined as
R = I n, i [(l/Ci)(lXexptI(Ki)-Xth(Ki)l)] x 100% (3)
where N is the number of data points, Xexptl(Ki) is the experimental EXAFS, Xth(Ki) 
is the calculated EXAFS, and a , is defined as
1/cjj = Kin/lN , j Kjn lxexpll(*j)l (4)
where n is a number chosen so that KnxexPtl(K) has approximately constant amplitude 
over the data range.
Results and Conclusion
Protein Purification and Assay. Mutant human adenosine deaminases, 
including Glu217Ala and His238Ala, were originally purified in a one-column 
procedure by immunoaffinity chromatography (Bhaumik et al., 1993). To avoid 
exposing the proteins to a denaturant we chose an alternative purification scheme. 
Glu217Ala and His238Ala have about the same affinities for substrate and inhibitors 
as wild-type enzyme (Zeng et al., 1996), so the mutant proteins are purified by ligand 
affinity chromatography in a two-step procedure involving DEAE-Sephadex and 
purine riboside-Sepharose columns. After the ion-exchange column, the mutant 
proteins are retarded on the purine riboside affinity column and are eluted
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Table 3.1. Purification of Glu217Ala and His238Ala mutant human adenosine deaminases from recombinant 
baculovirus-infected insect larvae.
mutant fraction
total protein 
(mg)
volume (mL) enzyme units 
(units)
specific activity 
(units/mg)
Glu217Ala
crude extract supernatant 389 82 6.2 0.0159
DEAE eluate 106 425 ND" ND
PR-Sepharose eluate 11.1 1 0.25 0.02
His238Ala
crude extract supernatant 280 80 4.7 0.02
DEAE eluate 80 400 ND ND
PR-Sepharose eluate 4.08 1 0.52 0.13
"Not determined.
0\
00
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isocratically. A sample scheme is shown in Table 3.1. The prep is scaled to about 
25 g o f larvae, which yield 6-11 mg of GIu217Ala and 3-9 mg of His238Ala. Yields 
o f wild-type human adenosine deaminase are 4-10 mg purified by purine riboside 
affinity chromatography and 17-32 mg enzyme purified by adenosine affinity 
chromatography. Glu217Ala and His238Ala mutants show a single band of >95% 
purity on SDS-polyacrylamide gel electrophoresis. The specific activities of the 
mutant proteins purified by purine riboside chromatography agree with the values 
obtained by immunoaffinity chromatography (0.02 for Glu217Ala and 0.13 for 
His238Ala). The larvae have an endogenous deaminating activity that does not bind 
to the immunoaffinity column (Bhaumik et al., 1993). The finding of the same low 
specific activities for the mutant proteins purified by the two methods suggests that 
the larvae adenosine deaminase does not copurify with the recombinant mutant 
enzymes on the purine riboside column.
Wild-Tvpe Human Adenosine Deaminase. The fluorescence-detected 
background-corrected Zn K-edge X-ray absorption spectra for free enzyme, HDPR, 
and l-deazaadenosine complexes of wild-type human adenosine deaminase are 
depicted in Figure 3.1. The relative height of the two peaks located at energies 9.716 
and 9.742 Kev on the edge of the XAS varies substantially among the three enzyme 
forms. Since the near edge region is sensitive to the coordination geometry of the 
Zn, the differences suggest that structural changes occur at the active-site Zn of 
wild-type adenosine deaminase upon binding of ground- and transition-state analog 
inhibitors.
The fc3-weighted EXAFS x (x ) of the wild-type adenosine deaminase 
complexes with transition-state analog inhibitor HDPR and ground-state analog 
inhibitor 1-deazaadenosine are shown in Figures 3.2a and 3.3a. The Zn EXAFS of 
different forms of adenosine deaminase is relatively strong without a clear beat
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Figure 3.1. The Zn K-edge X-ray absorption spectra of wild-type human adenosine deaminase for (O) free enzyme, (+ )  
complexed with ground-state analog inhibitor 1-deazaadenosine, and (A) complexed with transition-state analog inhibitor 
HDPR.
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Figure 3.2. Experimental (— ) and fit (••••) (a) EXAFS; (b) Fourier transform of 
wild-type human adenosine deaminase complexed with transition-state analog 
inhibitor HDPR.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
72
5 --fit
0
•5
4 6 8 10 12 14
K
1.6
exp
1.4
1.2
0.8
0.6
0.4
0.2
_ /
0
65430 ■>
R
Figure 3.3. Experimental (— ) and fit ( - • )  (a) EXAFS; (b) Fourier transform of 
wild-type human adenosine deaminase complexed with ground-state analog inhibitor 
1-deazaadenosine.
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pattern. The Fourier transforms of EXAFS from 2.5-13 A '1 in fc-space are shown in 
Figures 3.2b and 3.3b for HDPR and 1-deazaadenosine complexes, respectively. 
Again, both the EXAFS raw data and their Fourier transforms show sizable changes 
between different enzyme forms. The Fourier transform is dominated by a single 
well-resolved peak centered at about 1.8 A with a few minor peaks above the noise 
between 2 and 4 A. The dominant feature can be simulated by three Zn-N/O 
interactions, but two additional Zn-N/O interactions near 2.3 and 1.8-2.1 A are 
necessary in order to get a good fit (Table 3.2). The EXAFS and Fourier transform 
patterns o f wild-type adenosine deaminase are similar to those observed in EXAFS 
studies of Zn carboxypeptidase A, which has five Zn-N/O coordination (Zhang et al., 
1992; Zhang & Auld, 1993).
The EXAFS data were fit assuming four or five ligands coordinated to Zn. 
When the EXAFS is analyzed with McKale curved-wave single-scattering theory, 
distinctly better fits are obtained for the inhibitor complexes with a five-coordinate 
N/O shell (F factor < 35) than with a four-coordinate N/O shell (F factor > 90). The 
small features present beyond the central 1.8 A peak are probably due to 
multiple-scattering interactions from the three imidazole groups of His 15, His 17, and 
His214 with some contributions from oxygens and carbons o f Glu217, His238, 
Asp295, Asp296, G lyl84, and the bound inhibitors within 6 A of the Zn. The 
analyses of these EXAFS data are greatly improved by using the multiple-scattering 
formalism with Cerius2 (data not shown). The 6-hydroxyl group in HDPR complex 
and the activated water/hydroxide in 1-deazaadenosine complex are omitted in the 
four-coordinate multiple-scattering fits.
The crystal structure models o f ground- and transition-state analog inhibitor 
complexes o f mouse adenosine deaminase do not fit the profile of EXAFS 
experimental results of the corresponding complexes of human enzyme (Figure 3.4).
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Figure 3.4. Experimental EXAFS of wild-type human adenosine deaminase and 
calculated EXAFS from X-ray coordinates of mouse adenosine deaminase (a) 
complexed with ground-state analog inhibitor 1-deazaadenosine; (b) complexed with 
transition-state analog inhibitor HDPR.
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There are two possible explanations for the discrepancy. First, there are subtle 
differences in the environment of the active-site Zn in mouse and human enzyme. 
Second, the apparent differences in Zn-ligand distances are within the experimental 
error o f the two techniques. The root-mean-square error in interatomic distances of 
these complexes from X-ray diffraction is 0.2-0.3 A (Wilson et al., 1991), whereas 
EXAFS error may be as small as 0.02 A. Therefore, EXAFS analysis considering 
multiple-scattering most likely presents an accurate picture o f the active-site Zn 
environment for adenosine deaminase.
For the human adenosine deaminase complex with transition-state analog 
inhibitor HDPR, two of the Zn-N distances determined by EXAFS are identical 
within error to the X-ray diffraction distances for the mouse enzyme complex and the
o
other three Zn-ligand distances are 0.1-0.2 A shorter (Table 3.2). There are five N/O 
ligands coordinated to active-site Zn. The four-coordinate fit of EXAFS gives an 
unacceptable F factor of 96.4 compared to 26.9 for the five-coordinate fit. The 
five-coordination of Zn confirms the hydration o f the inhibitor purine riboside to 
HDPR in the enzym e-inhibitor complex observed by 13C-NMR and X-ray 
diffraction (Kurz & Frieden, 1987; Wilson et al., 1991). However, the Zn-0 distance 
to 0 6  of HDPR is only 2.06 ± 0.02 A, significantly shorter than the X-ray value of 
2.29 A. These results provide strong support for the coordination environment of the 
active-site Zn in the transition-state analog inhibitor complex determined by X-ray 
crystallography though give slightly different values for three of the Zn-ligand 
distances.
For the human adenosine deaminase complex with ground-state analog 
inhibitor 1-deazaadenosine, the EXAFS results also offer strong support for the 
five-coordination environment of the active-site Zn found by X-ray crystallography 
for the mouse adenosine deaminase complex. Four o f five EXAFS Zn-ligand
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Table 3.2. EXAFS results for wild-type human adenosine deaminase.
Free ADA ADA/DAA Complex ADA/PR Complex
R (o ) (A ) R ( a ) ( A ) R c a  (A ) R ( a )  (A ) R ca (A )
Zn-N 2.24 (0.03) 2.11 (0.04) 2.24 2.29 (0.06) 2.31
Zn-N 2.06 (0.02) 2.12(0.04) 2.03 2.14 (0.05) 2.16
Zn-N 2.07 (0.02) 2.00 (0.02) 1.59 2.14(0.05) 2.23
Zn-0 2.24 (0.03) 2.19(0.02) 2.27 2.27 (0.02) 2.40
Zn-O 1.73 (0.04) 1.82 (0.02) 1.80 2.06 (0.02) 2.29
F4c 123.3 102.1 ND* 96.4 ND
p5r/ 32.6 5.6 ND 26.9 ND
flZn-ligand distance from X-ray crystal structure of mouse adenosine deaminase. ^Not determined. cF-factor for four- 
coordinate fits. ^F-factor for Five-coordinate fits.
-i
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distances are within about 0.1 A o f the X-ray values. However, one Zn-N distance
p
from EXAFS is 0.4 A longer. Here too, the four-coordinate fit is rejected because of 
poor F factor of 102.1 compared to 5.6 for the five-coordinate fit. Five-coordination 
of the active-site Zn confirms the activated water or hydroxide proposed in the X-ray 
crystal structure (Wilson & Quiocho, 1993). The Zn coordination sphere o f the 
ground-state analog inhibitor complex is smaller than that o f the transition-state 
analog inhibitor complex in both human and mouse wild-type adenosine deaminases. 
EXAFS data show: (1) In the HDPR complex, two o f the His residues are 0.1-0.2 A 
farther from Zn then they are in the deazaadenosine complex. (2) The Zn-0 distance 
to Asp295 decreases from 2.27 ±  0.02 A in the HDPR complex to 2.19 ±  0.02 A in 
the deazaadenosine complex. (3) The Zn-0 distance to 0 6  of HDPR is 2.06 ±  0.02 
A compared to the Zn-water/hydroxide distance o f 1.82 ±  0.02 A in the 
deazaadenosine complex.
In the case o f free human adenosine deaminase, the corresponding crystal 
structure for mouse enzyme is not available. Therefore, coordinates for the mouse 
enzyme complexes with ground- and transition-state analog inhibitors were used as 
starting geometries in EXAFS analyses. The atoms in the purine rings within 6 A 
from Zn were removed for the multiple-scattering analyses. The four-coordinate fit 
o f EXAFS of free enzyme also gave a poorer fit with F factor of 123.3 compared to 
32.6 for a five-coordinate fit. This indicates that there are five coordination sphere 
N/O ligands bound to active-site Zn and provides the first evidence of an "activated 
water" in free adenosine deaminase. Thus, it appears that the water is ordered or 
activated and ready to attack the substrate prior to formation of the Michaelis 
complex. The activation o f the water molecule and tendency to form and localize the 
hydroxide are favored by the alignment of Zn and some active-site amino acid 
residues, such as His238 and Asp295 in free adenosine deaminase. Inspection of the
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crystal structures o f the two mouse enzyme complexes reveals three likely 
interactions between the water molecule and active-site ligands in the free enzyme: 
coordination of the water oxygen to the powerful Zn electrophile plus hydrogen 
bonding of one water hydrogen to 051 of Asp295 and of the other hydrogen to Ne2 
of His238. The Zn-0 distance from "activated water" is shorter in free enzyme (1.73 
±  0.04 A) than in ground-state analog inhibitor complex (1.82 ±  0 .0 2  A), suggesting 
that the binding of ground-state substrate plays a role in the displacement of the 
"activated water" to form the hydroxyl in the transition state.
Structures o f the active sites o f enzymes are modified by the binding of 
substrate or inhibitor, as was postulated by Koshland (1958) more than three decades 
ago and reexamined by Post and Ray (1995) recently. These conformational changes 
upon binding of substrate or inhibitor orient functional groups on the enzyme to 
enhance efficiency of formation o f the transition state as well as subsequent chemical 
processes. This type of dynamic recognition is defined as induced fit. In the case of 
adenosine deaminase, starting from free enzyme, the active-site Zn coordination 
environment is close to that o f ground-state analog inhibitor complex. This is 
evident by comparing the EXAFS results of free human adenosine deaminase and its 
ground-state analog inhibitor complex. Five ligands are coordinated to active site Zn 
with similar Zn-ligand distances. This tells us that the active site structure is 
maintained upon binding of 1-deazaadenosine, a ground-state analog inhibitor of the 
enzyme, and suggests that the active site of adenosine deaminase is designed to fit 
the ground state o f substrate. In contrast, significant changes in active-site Zn 
coordination environment occur after the enzyme binds purine riboside, which is 
hydrated at C6  immediately after binding and forms the near ideal transition-state 
analog HDPR with a tetrahedral structure at C6 . The induced fit in adenosine 
deaminase in the transition state expands the coordination sphere of Zn by about 0.1
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A, especially the Z n-0  distance to activated water/hydroxide or 0 6  of HDPR (from 
1.73 ± 0.04 in free enzyme to 2.06 ± 0.02 in HDPR complex), well beyond the error 
in the EXAFS results. Since hydroxide is a better proton acceptor than hydroxyl, the 
Zn-OH' distance is generally about 0.2 A shorter than the Zn-OH distance in small 
inorganic compounds (Kimura et al., 1990), in agreement with the EXAFS results. 
His 15, H isl7 , His214, and Asp295 open up and pull away from Zn, while the 
water/hydroxide moves away from Zn and presumably closer to C6  of the inhibitor 
to form the transition state of the substrate. This increase in size o f  the Zn 
coordination sphere from ground-state to transition-state enzyme complex is also 
apparent in the X-ray structures of mouse adenosine deaminase complexes with 
ground- and transition-state analog inhibitors (Wilson et al., 1991; W ilson & 
Quiocho, 1993). Previously, fluorescence studies demonstrated that adenosine 
deaminase undergoes different conformational changes upon binding of ground- and 
transition-state analog inhibitors (Kurz et al., 1985; Philips et al., 1987; Philips et al.,
1989).
Free Enzymes and Ground-State Analog Inhibitor Complexes o f  Mutant 
Human Adenosine Deaminases. The biochemical and biophysical properties of 
Glu217Ala and His238Ala mutants were characterized previously (Bhaumik et al., 
1993; Zeng et al., 1996). Substitution o f Glu217 or His238 by alanine causes 
complete loss o f enzyme activity and 30 or 50% loss of a -h e lica l content, 
respectively. However, both mutants retain normal substrate and inhibitor binding 
affinity and P-sheet content. Apart from the missing carboxylic acid group of 
Glu217 or imidazole group of His238, the enzyme active site inside the P-barrel 
appears to be largely intact. The EXAFS data analysis of free and ground-state 
analog inhibitor complexes of these two mutants improves significantly for five- 
coordinate fits compared to four-coordinate fits as shown in Tables 3.3 and 3.4.
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Table 3.3. EXAFS results for Glu217Ala mutant human adenosine deaminase.
Free ADA 
R (a) (A)
ADA/DAA Complex 
R (a) (A)
ADA/PR Complex 
R(a)(A)
Zn-N 2.29 (0.05) 2 . 1 2 (0 .0 2 ) 2.29 (0.05)
Zn-N 2.08 (0.03) 2 . 1 2 (0 .0 2 ) 2.20 (0.05)
Zn-N 2.08 (0.03) 2.03 (0.04) 2.05 (0.02)
Zn-O 2.25 (0.03) 2.23 (0.07 ) 2.17 (0.04)
Zn-0 1 .6 8  (0.06) 1.79 (0.02) 1.69 (0.06)
f 4« 98.7 111.7 106.4
f 5* 18.1 7.3 24.3
°F-factor of four-coordinate Fits. ftF-factor of five-coordinate fits.
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EXAFS of free and ground-state analog inhibitor complexes of GIu217Ala 
and His238Ala mutants gives the following results: (1) The Zn-ligand distances of 
the two free mutant enzymes are almost identical to those o f free wild-type enzyme, 
with a root-mean-square deviation of 0 .0 1  A for both mutants. This confirms that 
the structure of the active site of Glu217Ala and His238Ala mutants is not perturbed 
by the amino acid replacement (Zeng et al., 1996); (2) There is also remarkable 
similarity among the three ground-state analog inhibitor complexes of wild-type, 
Glu217Ala, and His238Ala adenosine deaminases; and (3) The Zn-ligand distances 
in the active site of free enzyme are similar to those of deazaadenosine complex for 
both Glu217Ala and His238Ala mutants, with root-mean-square deviations of 0.04 
and 0.03 A for Glu217Ala and His238AIa, respectively. The mutant results 
strengthen the conclusion that there is little conformational change in the active site 
of adenosine deaminase upon binding of ground-state inhibitor.
Transition-State Analog Inhibitor Complexes of Mutant Human Adenosine 
D eam inases. The EXAFS data analysis of transition-state analog inhibitor 
complexes of these two mutants also indicates Five-coordination o f the active-site Zn 
(Tables 3.3 and 3.4). Unlike the free enzymes and ground-state analog inhibitor 
complexes, the complexes o f the mutants with the transition-state analog inhibitor 
purine riboside have different active site geometries. For Glu217Ala mutant, the 
Zn-ligand distances are almost identical in the free enzyme and purine riboside 
complex apart from one Zn-N distance. The purine riboside complex of Glu217Ala 
mutant differs from the HDPR complex of wild-type enzyme. Especially the Zn-O 
distance to 0 6  on HDPR in wild-type enzyme complex of 2.06 ± 0.02 A is replaced 
in the mutant complex by a much shorter Zn-0 distance of 1.69 ±  0.06 A. This short 
Z n-0  distance in the purine riboside complex of Glu217Ala is identical to the
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Table 3.4. EXAFS results for His238Ala mutant human adenosine deaminase.
Free ADA 
R (a) (A)
ADA/DAA Complex 
R « t)(A)
ADA/PR Complex 
R (a) (A)
Zn-N 2.26 (0.04) 2.18(0.02) 2.31 (0.06)
Zn-N 2.04 (0.03) 2.13(0.05) 2.15 (0.05)
Zn-N 2.09 (0.04) 2 .0 0  (0 .0 2 ) 2.14(0.05)
Zn-0 2.25 (0.03) 2.29 (0.02) 2.26 (0 .0 2 )
Zn-O 1 .6 8  (0.06) 1.69(0.04) 2.07 (0.02)
F4° 97.7 136.8 111.9
f5* 22.3 23.8 25.4
aF-factor of four-coordinate fits. 6 F-factor of five-coordinate fits.
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1 .6 8  ±  0.06 A Zn-O distance in the free enzyme. It is too short to be a Zn-hydroxyl 
distance and likely represents a Zn-0 distance from activated water/hydroxide, 
consistent with formation of a ground-state complex. However, the Zn-0 distance in 
purine riboside complex is about 0 .1  A shorter than the corresponding distance in the 
ground-state analog inhibitor complex with 1-deazaadenosine, perhaps due to the 
presence of the amino group of adenosine.
The above conclusion from EXAFS agrees with results from previous studies 
of Glu217 mutants of mouse adenosine deaminase by solvent difference UV and 
13C-NMR spectroscopies (Mohamedali et al., 1996). In the proposed catalytic 
mechanism o f adenosine deaminase based on X-ray diffraction studies o f 
ground- and transition-state analog inhibitor complexes of mouse enzyme, Glu217 is 
an active-site amino acid residue (Wilson et al., 1991; Wilson & Quiocho, 1993). 
The carboxylic acid group of Glu217 protonates the purine ring. In Glu217Ala 
mutant, Ala obviously is unable to carry out the function o f Glu without the 
carboxylic acid group. A more conservative substitution, such as Glu217Asp, should 
retain the ability to form the tetrahedral transition state, thus preserving more 
catalytic activity. The mouse Glu217Asp mutant has 20-fold higher specific activity 
than the human Glu217Ala mutant (mouse and human wild-type adenosine 
deaminases have the same specific activity; Mohamedali et al., 1996).
For the purine riboside complex of His238Ala mutant, the EXAFS results are 
similar to the HDPR complex of wild-type enzyme. The Z n-0  distance of 
His238Ala purine riboside complex increases almost 0.4 A compared to the free 
mutant enzyme and ground-state analog inhibitor complex. The mutant complex has 
almost identical Zn-ligand distances as the HDPR complex of wild-type enzyme. 
This is strong evidence for formation of the transition state in the purine riboside 
complex of His238Ala. In the most recent mechanism o f adenosine deaminase,
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His238 is proposed to play two roles in catalysis (Wilson & Quiocho, 1993). In the 
first step, it acts as a general base in abstracting a proton from the activated water 
and stablizing the pre-transition state. After formation o f the transition state, the 
abstracted proton on Ne2 of His238 acts as a proton donor to the N6  amino leaving 
group of substrate. Our EXAFS results show five cordination of the Zn for wild-type 
and mutant enzymes in the absence and presence of inhibitors, suggesting that there 
is always an activated water molecule or hydroxyl ligand on the Zn. The activation 
of the water molecule is facilitated by coordination of water oxygen to the powerful 
Zn electrophile and donation o f one hydrogen to a hydrogen bond with 051 of 
Asp295. Therefore, it is not surprising that the water is able to act as a weak 
nucleophile attacking C6  of substrate to form a tetrahedral transition state without 
help from His238 when all the other important active-site ligands, such as Asp295 
and Zn, are present. Nevertheless, the catalytic activity of His238AIa has dropped 
3000-fold com pared to wild-type, though kcat is about 5 times higher than 
Glu217Ala (Bhaumik et al., 1993; Zeng et al., 1996). What makes the His238 so 
essential after the successful formation of the transition state? It seems to be related 
to the second role o f His238 in catalysis. Without the imidazole group of His238 
proton donation to the N6  amino group cannot occur, which obviously hinders the 
deamination.
References
Akedo, H., Nishihara, H., Shinkai, K., Komatsu, K., & Ishikawa, S. (1972) Biochim. 
Biophys. Acta 276, 257-271.
Antonini, I., Cristalli, G., Franchetti, P., Grifantini, M., Martelli, S., & Petrelli, F. 
(1984) J. Phartn. Sci. 73, 366.
Aran, J. M., Canela, E. I., & Franco, R. (1990) J. Chromatogr. 532, 75-85.
Ball, L. J., Diakun, G. P., Gadhavi, P. L., Young, N. A., Armstrong, E. M., Gamer, 
C. D., & Laue, E. D. (1995) FEBS Lett. 358, 278-282.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
85
Bhaumik, D., Medin, J., Gathy, K., & Coleman, M. S. (1993) J. Biol. Chem. 268, 
5464-5470.
Bracey, M. H., Christiansen, J., Tovar, P., Cramer, S. P., & Bartlett, S. G. (1994) 
Biochemistry 33, 13126-13131.
Bradford, M. M. (1976) Anal. Biochem. 72, 248-254.
Carson, D. A., Kaye, J., & Seegmiller, J. E. (1977) Proc. Natl. Acad. Sci. USA 74, 
5677-5681.
Chance, M. R., Sagi, I., Wirt, M. D., Frisbie, S. M., Scheming, E., Chen, E., Bess, J. 
W., Jr., Henderson, L. E., Arthur, L. O., South, T. L., Perez-Alvarado, G., & 
Summers, M. F. (1992) Proc. Natl. Acad. Sci. U.S.A. 89, 10041-10045.
Citrin, P. H., Eisenberger, P., & Kincaid, B. M. (1976) Phys. Rev. Lett. 36, 
1346-1349.
Cramer, S. P. (1987) in X-ray Absorption: Principles, Applications, Techniques o f  
EXAFS, SEXAFS, XANES (Koningsberger, D. C., & Prins, R., Ed.), pp 257- 
320, Wiley, New York.
Cramer, S. P., & Hodgson, K. O. (1979) Prog. Inorg. Chem. 25, 1-39.
Cramer, S. P., Hodgson, K. O., Stiefel, E. I., & Newton, W. O. (1978) J. Am. Chem. 
Soc. 100, 2748-2760.
Cramer, S. P., Tench, O., Yocum, M., & George, G. N. (1988) Nucl. Instrum. 
Methods Phys. Res. Sect. A 266, 586-623.
Daddona, P. E„ & Kelly, W. N. (1977) J. Biol. Chem. 252, 110-115.
Dent, A. J., Beyersmann, D., Block, C„ & Hasnain, S. S. (1990) Biochemistry 29, 
7822-7828.
Edwards, Y. H., Hopkinson, D. A., & Harris, H. (1971) Ann. Hum. Genet. 35, 
207-219.
Eggers-Borkenstein, P., Priggemeyer, S., Krebs, B., Henkel, G., Simonis, U„ 
Pettifer, R. F., Nolting, H.-F., & Hermes, C. (1989) Eur. J. Biochem. 186, 
667-675.
Eisenberger, P., & Lengeler, B. (1980) Phys. Rev. B 2 2 ,3551-3561.
Fay, M. J., Proctor, A., Hoffmann, D. P., & Hercules, D. M. (1988) Anal. Chem. 60, 
1225-1243.
Feiters, M., & Jeffery, J. (1989) Biochemistry 28, 7257-7262.
Garcia, G. A., Tierney, D. L., Chong, S., Clark, K., & Penner-Hahn, J. E. (1996) 
Biochemistry 35, 3133-3139.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Gamer, C. D. (1991) Adv. Inorg. Chem. 36, 303-339.
Garner, C. D., & Feiters, M. C. (1987) in Biophysics and Synchrotron Radiation
(Bianconi, A., & Congiu-Castellano, A., Ed.), pp 136-146, Springer-Verlag, 
Berlin.
Gurman, S. J. (1988) J. Phys. C: Solid State Phys. 21, 3699.
Gurman, S. J., Binsted, N., & Ross, I. (1984) J. Phys. C: Solid State Phys. 17, 
143-151.
Gurman, S. J., Binsted, N., & Ross, I. (1986) J. Phys. C: Solid State Phys. 19, 
1845-1861.
Hirschhom, R. (1975) J. Clin. Invest. 55, 661-667.
Jaklevic, J., Kirby, J. A., Klein, M. P., Robertson, A. S., Brown, G. S., &
Eisenberger, P. (1977) Solid State Commun. 2 3 ,679-698.
Kimura, E., Shiota, T., Koike, T., Shiro, M., & Kodama, M. (1990) / .  Am. Chem. 
Soc. 112, 5805-5811.
Koshland, D. E. J. (1958) Proc. Natl. Acad. Sci. U.S.A. 44, 98-104.
Kurz, L. C., & Frieden, C. (1987) Biochemistry 26, 8450-8457.
Kurz, L. C., LaZard, D., & Frieden, C. (1985) Biochemistry 24, 1342-1346.
Laemmli, U. K. (1970) Nature 227, 680-685.
Lee, P. A., Citrin, P. H., Eisenberger, P., & Kincaid, B. M. (1981) Rev. Mod. Phys. 
53, 769-806.
Lida, A. (1991) Trends Anal. Chem. 10, 215-222.
Liu, J., Gagnon, Y., Gauthier, J., Furenlid, L., L'Heureux, P.-J., Auger, M., Nureki, 
O., Yokoyama, S., & Lapointe, J. (1995) J. Biol. Chem. 270, 15162-15169. 
Medin, J. A., Hunt, L., Gathy, K., Evans, R. K., & Coleman, M. S. (1990) Proc. 
Natl. Acad. Sci. USA 87, 2760-2764.
M ohamedali, K. A., Kurz, L. C., & Rudolph, F. B. (1996) B iochem istry  35, 
1672-1680.
Mustre de Leon, J., Rehr, J. J., & Zabinsky, S. I. (1991) Phys. Rev. B 4 4 ,4146-4156.
Navaratnam, S., Myles, G. M., Strange, R. W., & Sancar, A. (1989) J. Biol. Chem. 
264, 16067-16071.
Ogawa, T., Aikawa, Y., & Aikawa, T. (1987) Comp. Biochem. Physiol. 88B, 
491-495.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
87
Osborne, W. R. A., & Spencer, N. (1973) Biochem. J. 133, 117-123.
Philips, A., Robbins, D., Barkley, M. D., & Coleman, M. S. (1987) Biochemistry 26, 
2893-2903.
Philips, A. V., Coleman, M. S., Maskos, K., & Barkley, M. D. (1989) Biochemistry 
28, 2040-2050.
Post, C. B., & Ray, W. J. J. (1995) Biochemistry 34, 15881-15885.
Priggemeyer, S., Eggers-Borkenstein, P., Ahlers, F., Henkel, G., Komer, M., Witzel, 
H., Nolting, H.-F., Hermes, C., & Krebs, B. (1995) Inorg. Chem. 34, 
1445-1454.
Randall, C. R., Zang, Y., True, A. E., & Que, L., Jr. (1993) B iochem istry  32, 
6664-6673.
Rehr, J. J., & Albers, R. C. (1990) Phys. Rev. B 41, 8139-8149.
Rehr, J. J., Albers, R. C., & Zabinsky, S. I. (1992) Phys. Rev. Lett. 69, 3397-3400.
Rehr, J. J., Mustree de Leon, J., Zabinsky, S. I., & Albers, R. C. (1991) J. Am. Chem. 
Soc. 113, 5135-5140.
Rowlett, R. S., Chance, M. R., Sidelinger, D. E., Royal, J. R., Woodroffe, M., Wang, 
Y.-F. A., Saha, R. P., & Lam, M. G. (1994) Biochemistry 33, 13967-13976.
Sansone, M., Via, G., George, G., Meitzner, G., Hewitt, R., & Marsch, J. (1991) 
X-Ray Absorption Fine Structure, Ellis Horwood, Ltd., W. Sussex, England.
Sayers, D. E„ Stem, E. A., & Lytle, F. W. (1971) Phys. Rev. Lett. 27, 1204-1207.
Schrader, W. P., & Stacy, A. R. (1977) J. Biol. Chem. 252, 6409-6415.
Schrader, W. P., Stacy, A. R., & PoIIara, B. (1976) J. Biol. Chem. 2 5 1 ,4026-4032.
Scott, R. A. (1985) Methods Enzymol. 1 1 ,414-459.
Sharff, A. J., Wilson, D. K„ Chang, Z„ & Quiocho, F. A. (1992) J. Mol. Biol. 226, 
917-921.
Sharpe, L. R. (1990) Chem. Rev. 9 0 ,705-722.
Simolo, K., Korszun, Z. R., Stucky, G., Moffat, K., McLendon, G., & Bunker, G. 
(1986) Biochemistry 25, 3773-3778.
Spencer, N., Hopkinson, D. A., & Harris, H. (1968) Ann. Hum. Genet. 32, 9-14.
Stem, E. A. (1974) Phys. Rev. B 10, 3027-3037.
Teo, B.-K. (1980) Acc. Chem. Res. 13, 412-419.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
88
Teo, B.-K. (1981) in EXAFS Spectroscopy, Techniques and Applications (Teo, 
B.-K., & Joy, D. C., Ed.), pp 13-58, Plenum, New York.
Thorvaldsen, J. L., Sewell, A. K., Tanner, A. M., Peltier, J. M., Pickering, I. J., 
George, G. N., & Winge, D. R. (1994) Biochemistry 33, 9566-9577.
Van der Weyden, M. B., & Kelly, W. N. (1976) J. Biol. Chem. 251, 5448-5456.
Wiginton, D. A., Coleman, M. S., & Hutton, J. J. (1981) Boichem. J. 195, 389-397.
Wilson, D. K., & Quiocho, F. A. (1993) Biochemistry 32, 1689-1694.
Wilson, D. K., & Quiocho, F. A. (1994) Struct. Biol. 1, 691-694.
Wilson, D. K., Rudolph, F. B., Harrison, M. L., Kellems, R. E., & Quiocho, F. A. 
(1988) /. Mol. Biol. 200, 613-614.
Wilson, D. K., Rudolph, F. B., & Quiocho, F. A. (1991) Science 252, 1278-1284.
Zeng, Q., Garthy, K., Coleman, M. S., & Barkley, M. D. (1996) Biochem istry  
submitted.
Zhang, K., & Auld, D. S. (1993) Biochemistry 32, 13844-13851.
Zhang, K., Chance, B., Auld, D. S., Larsen, K. S., & Vallee, B. L. (1992) 
Biochemistry 31, 1159-1168.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
APPENDIX
A. Construction of Recombinant Baculovirus for Wild-Type Human Adenosine 
Deaminase (Medin et al., 1990)
Human adenosine deaminase cDNA , the £coRI-£coRI fragment of a human 
adenosine deaminase clone (from a lambda phage gtlO library), is first inserted into 
the Eco RI site of pBR322 to generate plasmid pBR8 . pBR8  is digested with Hinf I, 
filled in with DNA polymerase Klenow fragment, and then digested with Nco I. 
This Nco I-blunt fragment is isolated from a low-melting temperature agarose gel 
and ligated into the pAcC4 baculoviral transfer vector DNA that has been prepared 
as illustrated in Figure A. 1. The vector DNA is digested with Bam HI, extended at 
the restriction site with the Klenow fragment, and then digested with Nco I to create 
a directed cloning site. The resulting construct is termed pAcC4ADA and is 
designed to encode a nonfusion protein after homologous recombination with 
AcMNPV, the insect baculovirus as illustrated in Figure A.2. AcMNPV 
(baculovirus DNA) is purified (Summers & Smith, 1987), and 1 (ig of purified 
extracellular virus DNA is combined with 2 jig of CsCl-purified pAcC4ADA 
transfer virus constructs in a cotransfection of Sf9 cells (Summers & Smith, 1987). 
Recombinant viruses that have undergone homologous recombination (designated 
AcMNPV) are identified by visual screening of plaque isolates in a plaque assay, 
facilitated by the uptake o f neutral red dye into uninfected viable cells (Brown & 
Faulkner, 1977; Summers & Smith, 1987). Putative recombinant viral isolates are 
identified as nonstained cells containing no polyhedrin protein occlusion bodies. 
Recombinant viruses are isolated and plaque-purified two or three times to obtain 
pure recombinant virus stocks. Blot hybridization and polymerase chain reaction are 
used to identify the recombinant virus.
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Figure A. 1. Construction of baculoviral transfer vector pAcC4ADA starting from vector pBR8 .
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Figure A.2. Synthesis of the pAcC4ADA baculoviral transfer vector and the recombinant virus AcMNPV adenosine deaminase.
Insect larvae are produced by hatching Trichoplusia n i eggs. Larvae (Fourth 
instar) are sedated by incubation on ice for 15 min and then injected near the proleg 
with 10 mL o f medium containing recombinant baculovirus. When optimum 
quantities of recombinant enzyme accumulated in the insects (4 days after injection), 
larvae are harvested and immediately frozen at -70 °C.
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B. Construction of Recombinant Baculovirus for Mutants of Human Adenosine 
Deaminase (Sambrook et al., 1989)
Construction of Vector M13nADA for Mutagenesis
The adenosine deaminase cDNA is cloned into vector M13nADA to facilitate 
the site-specific mutagenesis of selected regions. This construct is made as follows 
(Figure B .l). The adenosine deaminase cDNA is released from vector pBR8  as 
described in Appendix A with the restriction enzyme H inf I. Phosphorylated linker 
oligos (5'-AGTCCATGG-3') that convert the H in f  I site to an N co  I site are 
self-annealed and then added as duplexes (The phosphorylated linker oligos are in a 
50-fold molar excess compared to the cDNA of adenosine deaminase) and ligated to 
the H in f I ends obtained from the digestion. After a re-digestion with restriction 
enzyme Nco I, the cDNA with Nco I ends is subcloned into the baculoviral transfer 
vector at the Nco  I site as a shuttle intermediate. This vector is then identified as 
pAcC4ADA' to distinguish it from the vector pAcC4ADA used in the baculoviral 
expression. Large amount o f pAcC4ADA' are isolated and the plasmid is then 
digested with the restriction enzyme N co  I. After a phenol extraction step, 
phosphorylated N co  I to Eco RI linker duplexes (self-annealed) are added (The 
sequence o f the oligo is 5'-CATGGGAATTCC-3'.). The resulting ligation is 
digested w ith restriction enzyme E co  RI and the 1.1 kb band eluted onto 
nitrocellulose and extracted into TE buffer. The isolated adenosine deaminase 
cDNA is then ligated into dephosphorylated vector M13mpl8 at the Eco RI site and 
used to transfect frozen competent D H 5aF  cells. The orientation of the cDNA in 
the resulting vector M13nADA is then determined by restriction enzyme analysis. 
Construction of Single-Site Mutations
Vector M13nADA is used in the construction of all site-specific mutant 
forms of human adenosine deaminase. Single-stranded DNA containing uracil is
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Figure B .l. The Construction lineage of vector M13nADA and mechanism of the 
single-Site mutagenesis of human adenosine deaminase.
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made as described in the Bio-Rad Muta-Gene M13 in vitro mutagenesis kit (Bio-Rad 
labs, Richmond, CA).
Uracil-containing M13nADA is produced from strain BD2399 grown with 
the addition o f tetracycline and uridine. The cells are grown to an ODgoo o f 0.1. 
M13nADA phage is added at the recommended low multiplicity of infection (MOI).
The cells and phage are grown at 37 °C for 5 hr with vigorous shaking and 
then the uracil-containing phage are recovered as follows. The E. coli cells are 
pelleted by repeated centrifugation at 17,000 x g for 15 min in an SS-34 rotor 
(Sorvall) using polyallomer tubes. RNase is then added to the supernatant and the 
reaction incubated for 15 min at room temperature. To this reaction a solution of 
20% PEG-8000 containing 2.5 M NaCl is then added and the resulting product is 
incubated on ice for 30 min. The uracil-containing phage is recovered by 
centrifuging the above product at 17,000 x g for 20 min at 4 °C. The supernatant 
produced in this step is completely removed and the pellet resuspended in a high salt 
buffer (300 mM NaCl/100 mM Tris, pH 8/1 mM EDTA) and stored on ice for 30 
min. This stock solution is then extracted with phenol and phenol/chloroform/ 
iso-amyl alcohol directed in Muta-Gene kit. The purified single-stranded (containing 
uracil) M13nADA DNA is then subjected to analysis on a 1% TBE-agarose gel and 
quantitated by an A260 /A28O measurement.
Site-specific mutagenesis is performed as in the Muta-Gene kit protocol. 
Single-stranded uracil containing M13nADA is combined with phosphorylated 
mutagenic oligomers and annealing buffer (20 mM Tris-Cl, pH 7.4/2 mM MgCl2/50 
mM NaCl) and heated to 80 °C for 5 min. The reaction then is allowed to cool 
slowly to room temperature over 30 min and stored on ice. The second-strand 
synthesis reaction on the template and primer annealed product is accomplished by 
the addition of Sequenase v.II, DNA synthesis buffer (0.4 mM each dNTP/0.75 mM
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ATP/17.5 mM Tris-Cl, pH 7.4/3.75 mM MgCl2/21.5 mM DTT), and T4 DNA ligase. 
The reaction is incubated on ice for 5 min, incubated at room temperature for 5 min, 
and then heated to 37 °C for 90+ min. The DNA sample is electrophoresed on a 
0.8% TBE-agarose gel, and stained with EtBr to observe the shift in the molecular 
weight of the DNA bands upon second-strand synthesis. A significant shift to 
supercoiled and nicked circle forms is observed in the reactions including primers in 
contest to the lane where no primer is added. The reaction product, containing the 
newly synthesized second strand (without uracil residuals) is then used to transfect 
frozen competent DH5ocF cells. The isolates containing the mutations are screened 
by restriction analysis and sequenced to confirm the identity o f the mutation and to 
insure the fidelity of the surrounding nucleotides.
The mutated cDNAs in vector M13nADA are recloned into the baculoviral 
transfer vector pAcC4 at the N co  I site and expression analysis in the 
baculovims/Trichoplusia ni system is performed. Recombinant viruses are identified 
by PCR analysis and altered protein is made in each case. Expression and activity 
levels are analyzed in Sf9 cells and injected larvae as described in Appendix A.
The purification of recombinant mutants of human adenosine deaminase from 
injected larvae is accomplished using a monoclonal antibody column (Philips et al., 
1987), or a DEAE/purine riboside-Sepharose two-column process (Zeng et al., 
1996).
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C. EXAFSPAK: a Suite of Computer Programs for Analysis of X-Ray 
Absorption Spectra
The EXAFS is extracted from the raw X-ray absorption spectra data and 
analyzed to yield simulated EXAFS %(k) using EXAFSPAK, a suite o f computer 
programs for analysis of X-ray absorption spectra (documentation by Graham N. 
George, and Ingrid J. Pickering) (Cramer et al., 1978; Cramer & Hodgson, 1979; 
Teo, 1981; Scott, 1985).
MVIEW
The program MVIEW is used to plot data from X-ray absorption spectra. In 
X-ray absorption spectra collection, each individual XAS spectrum contains 8-10 
scans from different detector channels. All the scans are individually plotted and 
examined to confirm the absence of artifacts, and any scan showing irregularities is 
omitted for the further data processing.
MCALIB
The program MCALIB is used to re-calibrate data by reading a standard 
from a raw X-ray absorption spectrum file, which, in the case of human adenosine 
deaminase, is the transmission spectrum of Zn foil standard. The results are 
displayed on the terminal screen and written to an ASCII file Calibrate.Dat. The 
program searches for peaks in the derivative and uses a quartic polynomial fitted to 
the data, combined with a Newton Raphson search algorithm to accurately find peak 
positions.
MDEAD
The program MDEAD determines detector dead times from experimentally 
measured dead time curves and is designed for use with multi-element solid-state 
array detectors such as Canberra 1 elem ent ultrapure germ anium  array. 
Experimentally these measurements are made by scanning a slit blade through the
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incident X-ray beam while monitoring the output o f all the detectors. All photon 
counting detectors suffer from electronic dead time to some degree. The electronic 
dead time is primarily associated with the shaping amplifier. The correction method 
of electronic dead time depends on the collection o f a total incoming count rate 
signal from the shaping amplifier. This signal does not suffer from the same dead 
time effects as the shaped pulses, which are normally fed to a signal channel 
analyzer. The correction applied by MDEAD is for the type of extending or 
paralyzing dead-time, which is described as,
y=Kpe-PT (1)
where t  is the dead-time, y is the SCA, p is the ICR, and k is a constant of 
proportionality. MEAD reads a raw XAS data file containing a dead-time curve, 
determines the values of k, p, and x, so as to determine electronic dead-times and 
write the output file Deadtime.Dat. The .Dat files from MDEAD are used by 
MAVE.
MAVE
The 15-20 individual raw XAS spectra of each protein sample are computed 
to one output averaged data file (.AYE file) with MAVE program. MAVE is used 
for averaging raw XAS data files with electronic dead-time correction using the 
information in Deadtime.Dat if  needed. In addition to catering for simple 
transmittance spectra, MAVE is designed to convert data from multielement solid 
state detector arrays and therefore can perform energy calibration of the XAS data, 
and selective statistical weighting of individual data file array positions (channels) 
from array elements. The .AVE file generated from MAVE program is used by 
PROCESS and OPT programs for further data analyses.
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PROCESS
The .AVE file is used as an input file for program PROCESS for EXAFS 
data reduction manipulation: (i) pre-edge background subtraction by first-order 
polynomial fitting; (ii) above-edge background correction by two-region cubic spline 
fitting; (iii) normalization; (iv) data (a function of energy E) conversion to a function 
of k according to
k  =  [2me(E-Eo)/h2] I/2 = [0.262449(E -E o)]1/2 (2)
where k  is photoelectron wave vector and has a unit of A '1, me is electron mass, E is 
the photon energy, Eo (threshold energy) is the X-ray absorption edge energy and 
chosen as the photon energy at half-height of the absorption jum p, and h is the 
Planck's constant. The data are weighed to k 3 space to offset attenuation of the 
EXAFS signal with increasing photon energy; and (v) the resulting EXAFS data are 
Fourier transformed from energy space to radial distance space and different regions 
of the transform are back-transformed to yield Fourier-filtered spectra.(saved as .FIL 
files). The processed XAS data are re-written to either new .AVE files or Fourier- 
filtered .FIL files. Finally, the processed .AVE and .FIL files are used as the input 
files for OPT program. OPT is the EXAFS curve fitting analysis program and can 
use a variety of EXAFS phase and amplitude functions to obtain protein structural 
information. The simulated EXAFS is calculated as
X(k) = I { [ N sAs(k)Sc/kRas2]exp(-2K2aas2)exp(-2Ras/X)
sin[2kRas + 4>as(K)]} (3)
where x(k) is EXAFS amplitude function, Ns is the number of scattering atoms
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
100
within a shell, As(k ) is the curved-wave back-scattering amplitude o f the 
absorber-scatterer pair, Sc is the scaling factor that accounts for the effect of intrinsic 
processes and is specific to the absorber-scatterer pair, <7 a s 2 is the mean square 
deviation of the absorber-scatterer bond length Ras, O ^ k )  is the distance-dependent 
phase shift, and X is the photoelectron mean free-path.
OPT
OPT is the EXAFS curve fitting analysis program which is used to obtain 
structural information. It reads .AVE or .FIL files from PROCESS and can use a 
variety o f different phase and amplitude functions. These functions are the 
following: McKale curved wave theory, using 1/R interpolation to the initial value 
of distance; parameterized phase and amplitudes; Fourier filter extracted phase and 
amplitude functions from PROCESS; FEFF curved wave single scattering theory; 
FEFF curved wave multiple scattering theory; EXAFSPAK FEFF tables; and ASCII 
file input, phase and amplitude from some external source. The goodness o f a fit is 
evaluated by F-factors, which are the sum of the squares of the differences between 
experimental and calculated EXAFS curves.
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D. Abbreviations
A adenosine
AcMNPV autographa califomica nuclear polyhedrosis virus
ADA adenosine deaminase
2-APr 2-aminopurine riboside
ATP adenosine triphosphate
CCA convex constraint algorithm
CD circular dichroism
cps counts per second
DAA 1-deazaadenosine
dNTP deoxy-N triphosphate (N = adenosine, guanosine, thymidine, or
cytidine)
EPR electron paramagnetic resonance
EtBr ethidium bromide
EXAFS extended X-ray absorption fine structure
GdmCl guanidinium chloride
HDPR 6 (R)-hydroxy-dihydropurine riboside
I inosine
ICR incoming count rate
Kb kilo base pair
MOI multiplicity o f infection
NSLS National Synchrotron Light Source
PCR polymerase chain reaction
PR purine riboside
SCA signal channel analyzer
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SCID severe combined immunodeficiency disease
SSRL Stanford Synchrotron Radiation Laboratory
Sf9 Spodoptera frugiperda
XAS X-ray absorption spectroscopy
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F. Epilogue
At the time when this dissertation was defended, EXAFS data were analyzed 
with a single-scattering method as described in chapter 3. However, an improved 
data analysis was done recently with a multiple-scattering method using the Cerius2 
program. The new results confirm ed the existence o f the five-coordination 
environment for the active-site Zn of human adenosine deaminase, but were unable 
to distinguish the Zn-ligand distance differences among the free enzyme, and 
ground- and transition-state analog inhibitor complexes of wild-type and mutant 
adenosine deaminases. Detailed results will be presented in the following paper 
entitled "Zn-Binding Ligands at the Active Site of Human Adenosine Deaminase: an 
EXAFS Investigation," Qing Zeng, Karen Gathy, Mary Sue Coleman, and Mary D. 
Barkley, which is currently in preparation for subm ission to the journal 
Biochemistry.
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